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Abstract 
 
Since ancient times plants have been used in treatments and cures for several pathologies. 
Worldwide population growth, high cost of some therapies, side effects, and the increasing 
resistance to synthetic pharmaceuticals are some of the reasons for a bigger search for natural 
products, to be used in therapeutics and prevention of a large array of humans’ pathologies. 
Green tea is the second most consumed drink in the world and the health benefits of green tea 
have been recognized in the past, in particular the protection against cardiovascular, 
neurodegenerative and cancer diseases. Green tea polyphenols, strong antioxidants, of which (—
)-epigallocathechin-3-gallate (EGCG) is the most abundant, are considered the active components 
responsible for their anticancer properties. Studies have suggested a potential clinical activity for 
high doses of green tea in colorectal and breast cancer prevention. However, there are 
discrepancies between investigations and further controlled studies with adequate statistical 
treatment are needed. 
In this context, this study will focus on the anti-tumor properties of this tea,  applying them in a 
practical manner: adjuvant in the treatment of colon and breast cancer. The main goal of the work 
is to determine if green tea has a cytotoxic effect, due to the presence of the referred component 
(EGCG), over two human tumor cell lines – colon (WiDr) and breast (MCF-7) cancer –, its 
effectiveness in inhibiting their growth and if it can or not help potentiate specific chemotherapeutic 
agents, using well-defined clinical protocols. 
In this context an experimental study has been designed, divided in in vitro and in vivo studies, 
conducted on these cell lines.  
Several chemotherapy drugs with different actions were selected, and cell viability was 
determined by the MTT (bromide of 3-(4,5-dimethylthiazol,2-il)-2,5-diphenyl-tetrazolium) assay, 
which is based upon reduction of its tetrazolic ring through the formation of formazan crystals.  
In vivo studies of tumor induction were made through subcutaneous cell injection of the 
referred cell lines in a non-orthotopic model, in nude mice (BALB/c). The animals were organized 
in groups to test the efficacy of oral administration of GTE powder (11.605 g/500mL).  
The obtained in vitro studies’ results indicated that the EGCG treatment may diminish the cell 
viability of these tumor cells compared to the control group and may potentiate the cytotoxicity of 
the tested drugs. The results of the in vivo studies, as well as the images provided by the 
easyPET-3D system, proved the effective decrease of the tumor’s glandular structure in the 
animals following the defined protocol. 
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In conclusion, the aim is to further clarify if EGCG can be used as a natural added agent in the 
fight against colorectal and breast cancer, showing the experiments’ results. 
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Chapter 1  
1. Introduction 
 
This chapter will describe, in general, all the performed work. Initially, the problem of cancer 
affecting the world's population will be addressed, referring to updated statistical data in this area, 
giving rise to this study. Afterwards, a natural compound useful in cancer fight will be presented. 
Furthermore, the work plan, the used methodologies and the project structure will be presented, 
along with a brief summary of what is covered in each chapter.  
 
1.1 Contextualization and motivation 
Oncology is a branch of medical science linked to prevention, diagnosis and treatment of both 
benign and malignant tumors. Every cell in the human body has a well-regulated system that 
controls its growth, maturity, reproduction and death. The names “tumor” and “cancer” are often 
used as synonyms, but this is incorrect. A neoplasm corresponds to an abnormal cell growth 
(faster than normal), continuing if left untreated. The term “tumor” is commonly used, even if it is 
not specific, when referring to a neoplasm. Actually, tumor means only a mass. A neoplasm can be 
benign (usually curable) or malignant (cancerous). A benign tumor is usually localized and does 
not reach other areas of the body. The majority responds well to treatment, but if left untreated, it 
can become large and have serious consequences. A malignant "tumor" or cancer invades the 
surrounding tissues, breaking down the defense barriers and often offering resistance to treatment, 
leading to metastasis and sometimes reappearing even after surgical removal. Malignant tumors 
are the second leading cause of death worldwide. Lung, colorectal, breast and prostate cancer are 
the cancers responsible for most of the deaths [1]. 
Based upon statistical data, predicting an increase in new cancer cases over the years, it is 
essential to find compounds that not only prevent this disease, but also manage to treat it more 
effectively [2]. 
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In turn, there are references that, since prehistoric times, medicinal plants were used by 
almost all the civilizations of the globe. Today there are about 500.000 plant species on the planet 
and about 7.000 are or have been studied for medical applications. Furthermore, 25% of drug 
prescriptions currently contain compounds isolated from plants [2]. 
This study aims to relate one of the pathologies causing most of the deaths, with one very 
interesting plant, responsible for the most consumed infusion in the world, after water: tea. A 
practical example of the advantages of this compound is that, about 10 years ago, the Food and 
Drug Administration (FDA) approved the sale of sinecatechins (Veregen, Bradley/MediGene, AG, 
D82152 Planegg/Martinsried, Germany), a botanical drug used in the treatment of genital problems. 
Synechechin is an extract of green tea leaves from the Camellia sinensis plant, being the first 
herbal extract to be approved as a medicine for clinical therapy. The new drug, based on green 
tea, is now a real alternative to conventional therapy and shows how, thanks to the successful 
clinical trials of this tea and its catechins, this compound can lead to important beneficial 
formulations for health [2]. 
 
1.2 Study goals 
The health benefits of green tea have been recognized since ancient times, in particular the 
protection against cardiovascular, neurodegenerative and cancerous diseases. The polyphenols of 
green tea, strong antioxidants, of which epigallocatechin-3-gallate (EGCG) is the most abundant, 
are considered the active components responsible for the anticancer properties. Different studies 
have suggested a potential clinical activity for high doses of green tea to prevent colorectal and 
breast cancers. However, there are discrepancies between investigations and further controlled 
studies with adequate statistical treatment are needed []. 
In this context, this study aims to quantify the EGCG present in different brands of different 
green tea extracts, available on the market. It also aims to analyze the possible cytotoxicity of 
EGCG and its effectiveness in inhibiting the growth of two human tumor cell lines: colon (WiDr) and 
breast (MCF-7). 
Recently, in vitro and in vivo studies have been conducted with the WiDr cell line and with the 
drugs used to treat colorectal cancer, by adding an EGCG-enriched extract. Similar in vitro and in 
vivo studies were planned with the MCF7 cell line. This project also aims to contribute to the 
evaluation of green tea extracts to achieve a possible enhancement of the effect of the drugs used 
in their therapy, trying, in the future, to reduce the drug dosages or the therapeutic cycles. 
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Additional information was obtained from an in vivo study, conducted on an immune-
compromised animal model (BALB/c nude mice) injected subcutaneously (sc) with WiDr or MCF-7 
cell lines, in a non-orthotopic model to test the administration of EGCG-enriched green tea 
extracts. In summary, it is intended to further clarify how far EGCG can be used as a natural added 
agent in the fight against colorectal and breast cancer. 
 
1.3 Work structure 
This work is divided into 5 chapters. 
Chapter 1: Introduction 
This chapter discusses the contextualization of the work, as well as its goals. It intends to 
briefly explain how this project is divided and what are the main topics addressed. 
Chapter 2: Literature review 
This chapter first discusses statistical data on colorectal and breast cancer, being the topics 
that have guided this study.  
The stages of the referred tumors, and the different therapeutic regimens available for each of 
them are also explained. The cell lines chosen to perform this study (WiDr - colorectal cancer - and 
MCF-7 - breast cancer) are described, as well as the factors that led to their choice.  
Since it was intended to associate this oncological pathology with natural agents and tumor 
inhibitors, this interrelation was addressed, explaining the possible benefits of using natural plants 
or their derivatives/extracts. In particular, the Camellia sinesis plant that produces green tea and 
the (-) - epigallocatechin-3-gallate (EGCG), the main responsible polyphenolic compound for the 
health benefits associated with the consumption of green tea, have been analyzed. The 
chemotherapeutic agents for colorectal and breast carcinoma were then described. 
Finally, the animal model chosen to induce non-orthotopic colorectal and breast cancers, using 
the referred cell lines, was described. 
 Chapter 3: Material and methods 
This chapter discusses the procedures concerning these cell lines, as well as their 
achievement, for the performance of reproducible and coherent experiments. 
The green tea extracts studied and the analytical technique involved in determining the EGCG 
concentration present in each of them are described: high pressure liquid chromatography (HPLC). 
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The project has two distinct but converging parts: in vitro and in vivo tests. In the first case, the 
study procedures were explained and the study methodology of inducing cellular cytotoxicity was 
also described, explaining what the MTT test is (3-(4,5-dimethylthiazol-2-il)-2.5-
diphenyltetrazolium). In vivo studies were performed both with WiDr and MCF-7 lines, and 
independently evaluated and analyzed. The features of the animal model used for the 
subcutaneous inoculation of tumor cells, the development of non-orthotopic tumors and their 
occurrence, obeying and respecting to the by-laws of animal studies, were also described. 
 Chapter 4: Results and Discussion 
This chapter presents the results obtained with all the methods used in this project: in vitro and 
in vivo tests and their statistical analysis, using the SPSS and GraphPad Prism programs and, 
subsequently, their integrated critical analysis. 
 Chapter 5: Conclusion 
This chapter mentions the main conclusions drawn from this study and how they can 
contribute to further study and to enhance knowledge in the area. Furthermore, proposals for future 
works and analysis are also suggested. 
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Chapter 2 
2.   Literature review 
 
This chapter deals with the concepts used for the elaboration of the present study. 
 
2.1 Tumor vs cancer 
Tumor is an abnormal mass of tissue that results when cells divide more than they should or 
do not die when they should. Tumors may be benign (not cancer), or malignant (cancer), also 
called neoplasm [1,3].  
Cancer designates different types of related diseases. In all types of cancer, some of the 
body’s cells begin to divide without control and spread into surrounding tissues [3,4]. 
To better understand cancer, it is necessary to comprehend what happens to the cell in its 
normal life-time and how it can turn into a cancer cell. Human beings possess a huge variety of cell 
types in the body, most of which are replaced by new cells when they reach the end of the cell 
cycle. Thus, when cells become old or defective, they are destroyed and give rise to new cells with 
similar characteristics, in order to keep the organism functioning and healthy [5]. 
Sometimes the process of cell renewal does not take place correctly. Due to alterations in the 
genetic material, the cell loses the ability to control its growth, division and death.  Hence, cancer is 
caused by changes to genes, being a genetic disease. These genetic changes can be hereditary 
or arise during a person's life due to errors that occur when cells divide or due to DNA damages 
caused by different environmental exposures (such as radiation, chemicals in tobacco smoke or 
food preservatives) [5]. 
When cancer develops, the orderly process of cells’ growing and dividing breaks down. Cells 
become abnormal, and old or damaged cells survive when they should die, leading to cells’ 
formation when they are not needed [3-5]. 
The process of carcinogenesis may be divided into three stages: initiation, promotion, and 
progression. The first stage of carcinogenesis, initiation, results from an irreversible genetic 
alteration, likely one or more simple mutations, transitions, and/or small deletions in DNA. The 
reversible stage of promotion involves changes in the expression of the genome mediated through 
 8 
 
promoter-receptor interactions. The final irreversible stage of progression is characterized by 
instability and malignant growth [3-5]. 
Cancers are malignant tumors, which means they can spread into nearby tissues and, as 
these tumors grow, some cancer cells can break off and travel to distant places in the body 
through the blood or the lymphatic system and form new tumors far from the original one [3]. 
Cancer cells differ from normal cells in many ways that allow them to grow out of control and 
become invasive. One important difference is that cancer cells are less specialized than normal 
cells and, for this reason, cancer cells continue to divide without stopping, since they are able to 
ignore signals that normally tell cells to stop dividing or that begin the programmed cell death 
process (apoptosis) (Figure 1) [3]. 
 
Figure 1: Cancer cells and normal cells. Cancer cells divide  
uncontrollably and spread into surrounding tissues  
(retrieved from [3]). 
 
A cancer that has spread from the place where it first started to another site in the body is 
called metastatic cancer. The process by which cancer cells spread to other parts of the body is 
called metastasis (Figure 2) [3,4]. 
 
Figure 2: How normal cells become cancer cells:  initially the cells go through abnormal changes called 
hyperplasia (an increase number of cells appearing normal under a microscope) and dysplasia (the 
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cells look abnormal) and those states may or not become a cancer. These abnormal cells can 
invade the nearby tissues and blood/lymphatic vessels (retrieved from [3]). 
Cancer is a significant health problem worldwide, with very high incidences also in Europe. 
Nowadays it is the leading cause of death among the world's population (Figure 3) [6,7]. 
 
Figure 3: Study that reveals new cases of  tumor depending on the total  
number of people diagnosed with these tumors (retrieved  from [8]). 
The International Agency for Research on Cancer (IARC) estimate that one-in-five men and 
one-in-six women worldwide will develop cancer over the course of their lifetime, and that one-in-
eight men and one-in-eleven women will die from their disease. The factors appearing to be driving 
this increase, are a growing and ageing global population and an increase to the exposure to 
cancer risk factors linked to social and economic development  [6]. 
In 2018, 18.1 million new cancer cases and 9.6 million cancer deaths worldwide were 
estimated (Figure 4) [6]. 
 
Figure 4: Global cancer incidence (adapted from [6]). 
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Europe data refers 23.4% of total cancer cases and 20.3% of deaths, representing around one 
quarter of the global total of cancer cases with some 3.7 million new patients per year and 1.9 
million deaths each year (Figure 5). In Europe, cancer represents the second most important 
cause of death and morbidity. The most frequently diagnosed cancers are: lung, breast, prostate 
and colon types [8]. 
 
Figure 5: Estimated incidence in Europe by country, considering both sexes (adapted 
from [9]). 
 
Considering Italy, in accordance with the data presented by AIOM (Italian Association of 
Medical Oncology) and AIRTUM (Italian Cancer Registry Association), every day more than 1.000 
new cases of cancer are diagnosed. 
About 373.300 new cancer diagnoses during the year are estimated, 52% among men and 48% 
among women.  Considering the entire population, the most frequent tumors are the colorectal 
(13.7%) and breast (14.1%) cancer, followed by lung (11.1%) and prostate cancer (9.5% only in 
males) [10,11]. 
The good news is that overall recovery rates have improved over the past years thanks to the 
greater acceptance of screening campaigns, which allow the identification of the disease at an 
early stage, and the greater efficacy of the therapies [10,11]. 
Regarding Portugal, the country where this thesis project has been carried out, according to 
the data presented by the Portuguese League Against Cancer, cancer accounts for a quarter of 
deaths per year. Despite the increasing number of new people with cancer, care and survival with 
a good quality of life are more evident each time. The tumors causing the greatest number of 
deaths are colon, lung, breast and stomach cancer. As previously reported, the number of cases is 
always increasing and this may also be linked to the increase in average life expectancy, as this 
disease affects, in most cases, people of advanced age [8,12]. 
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In this context, it is necessary to discover new natural or synthetic compounds that can 
effectively prevent and/or help to treat this disease. 
In this project the focus has been on breast and colon cancer, two of the leading causes of 
death in the world population. 
 
2.2 Breast Cancer 
As mentioned above, cancer has emerged as the leading cause of morbidity and mortality in 
European populations. The most common diagnose among women worldwide is breast cancer, 
occurring with the highest incidence in developed countries including the EU, Australia, and the 
US, affecting approximately one in every ten women worldwide. It has been estimated that 12% of 
women will develop breast cancer over the course of their life [13,14].  
The development of this type of cancer is caused by a gradual and lifelong accumulation of 
acquired (somatic) mutations and epigenetic changes, that affect mammary tissue cells and their 
precursors. Examining cancer cells under the microscope, the presence of chromosomal 
aberrations was observed. The somatic mutations in a cancer cell genome may include distinct 
classes of DNA sequence change, such as substitutions of one base by another, insertions or 
deletions of small or large  segments of DNA and rearrangements [13-17]. 
A gene expression profiling of tumors has revealed five major molecular subtypes of breast 
cancer: basal-like, luminal A, luminal B, HER2+/ER–, and normal breast–like (Figure 6). The 
molecular differences result in distinct clinical outcomes and responses to treatment (Figure 7). 
These different subtypes are the explanation for the tumoral differences [18,19]. 
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Figure 6: Hypothetical models explaining breast tumor subtypes. Cell of origin (A) and  tumor 
subtype–specific transforming event (B) models (retrieved from [16]). 
 
 
 
 
Figure 7: Hypothetical model of breast tumor progression. Schematic view of normal, in situ, 
invasive, and metastatic carcinoma progression (retrieved from [16]). 
 
 
The molecular mechanism on the basis of hereditary changes that stimulate the development 
of breast cancer is not yet clear. However, it should be noted that most of the cancer susceptibility 
genes encode tumor suppressor proteins involved in DNA repair processes, especially the highly 
complex mechanisms of repair of DNA double-strand breakage  [20]. 
 
2.2.1 Breast anatomy 
The breast is an endocrine gland located on the front of the chest, consisting of glandular acini 
(alveoli), coated by cells that have the property of producing milk under the influence of some 
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hormones. Estrogen and progesterone induce changes in the glandular tissue depending on the 
period of the menstrual cycle. In the adult woman, the breast is made up of glandular tissue, 
connective and adipose tissue, that determine the size, shape and texture of the organ. The tissue 
is arranged in 15 to 20 lobes, each of which contains many lobules, terminating in clusters of 
rounded alveoli. The breast extends from the second rib above to the sixth rib below. Medially, it 
borders the lateral edge of the body of the sternum, and laterally it reaches the mid-axillary line [21-
23]. 
At the apex of the breast there is the mammary areola, a pigmented skin area whose surface is 
characterized by the presence of modified sebaceous glands that, with their secretion, have the 
function of making the nipple soft and elastic. At the surface of the nipple, there are tubules from 
which the secretion product of the gland comes out, especially when it is sucked by the offspring 
(Figure 8) [21-23]. 
 
Considering the histology, two components can be considered [24]:  
- structural component: the mammary stroma is responsible for supporting and protecting the 
mammary structure, dividing into an interlobular and intralobular stroma. The first one is 
mainly composed of dense connective and adipose tissue, which give its shape. The 
second one is composed of loose connective tissue, such as inflammatory cells or 
lymphocytes, resulting very sensitive to hormonal changes. The composition of the breast 
stroma changes over the years: it increases the adipose tissue and decreases the 
connective tissue 
- functional component: the breast parenchyma, made up of epithelial cells, is responsible for 
the production and secretion of milk. The mammary lobules are circular contour structures, 
formed by the grouping of acini and ducts surrounded by the interlobular stroma. The 
berries and the ducts are composed of two types of covering cells. The inner lining is 
formed by epithelial cells, and the outer one by myoepithelial cells responsible for the 
contraction to expel the milk produced. The distribution of the tissues (dense and loose, 
adipose and epithelial connective tissue) depends on the hormonal cycle, age, nutrition and 
genetic factors.  
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Figure 8: Anatomy of the breast (retrieved from [25]). 
 
 
2.2.1 Breast changes  
2.2.2.1 Benign 
Most breast changes, such as breast lumps or breast pain, are not signs of breast cancer. The 
most common causes of breast lumps are breast cysts1, fibroadenoma2, and breast calcification. 
Situation like intraductal papilloma3, fat necrosis4, and benign phyllodes tumor5 are less common 
causes for these breast lumps [26]. 
2.2.2.2 Cancer conditions 
The condition in which malignant (cancer) cells multiply abnormally in the breast eventually 
spreading to the rest of the body, is denominated breast cancer. Most tumors develops at the 
terminal end of the lobular units of the breast parenchyma. Signs of breast cancer include a lump, 
bloody nipple discharge, or skin changes [27].  
There are 4 main type of breast cancer (Figure 9) [27]:  
 ductal carcinoma in situ (DCIS): develops in the duct cells not invading deeper or spreading 
through the body. Women diagnosed with DCIS have a high likelihood of being cured; 
                                                          
1
 Fluid-filled sac that can develop as the breasts change with aging. 
2
 A lump that often develops during puberty, but which can occur at any age. 
3
 A wart-like lump developing in one or more milk duct of the breast. 
4
 A lump that forms itself when an area of fatty breast tissue is damaged. 
5
 Smooth, firm lumps in the breast, which, occasionally, grows fairly quickly and can be quite large (40–50 
mm). Sometimes the skin over the area can be inflamed. 
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 lobular carcinoma in situ (LCIS): occurs in the milk-producing lobule cells not invading or 
spreading to the rest of the body. However, women with LCIS have an increased likelihood of 
developing invasive breast cancer in the future; 
 invasive ductal carcinoma: begins in the duct cells, then invading deeper into the breast, 
carrying the potential of metastasizing; 
 invasive lobular carcinoma: begins in the milk-producing lobule cells, then progessing deeper 
into the breast, carrying the potential of spreading to the rest of the body (metastasizing). It is 
less common than invasive ductal carcinoma. 
 
 
Figure 9: Cross section of the breast and scheme of DCIS and LCIS (retrieved from [28,29]). 
 
2.2.3 Breast Cancer Classification  
Breast cancer is a heterogeneous disease that presents different phenotypic characteristics at 
histological, molecular and clinical level, especially considering the course of the disease and the 
therapeutic response. Breast cancers with different histopathological and biological features exhibit 
distinct behaviors, leading to different treatment responses and should be approached by different 
therapeutic strategies [30]. 
The microarrays have led to a new way in deciphering breast cancer heterogeneity, and a 
subtyping system using prognostic multigene classifiers was developed. In this context, in order to 
make the best therapeutic decisions, it is important to group breast cancers into clinically relevant 
subtypes. The technologic development allows to correlate the profile of the genic expression to its 
clinical evolution and its therapeutics response [30-33]. 
The classification should consider some aspects such as the histological type, the state of the 
hormonal receptors, the HER2 gene expression and the staging. The so-called intrinsic molecular 
classification of human breast cancer includes basal-like, HER2-positive, luminal-A and luminal-B 
subtypes [30-33]. 
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2.2.4 Histopathology  
      Histopathology and cytopathology are very important in the diagnosis of cancer, also providing 
information influencing prognosis and treatment [32-34]. 
Carcinomas are the most common malignant tumors of the breast, cancers derived from 
epithelial tissue. This means that they are mostly found in ducts or lobules, composed of granular 
tissue. Carcinomas have a wide range of subtypes that differ in terms of microscopic appearance 
and biological behavior. These specific tumor types are defined by their morphology, but are also 
linked to particular clinical, epidemiological, and molecular features [33,34]. 
It is important to distinguish between in situ and invasive carcinoma, in fact both types of 
carcinoma may possess similar symptoms and signs, although presentation as asymptomatic 
lesions detected during screening mammography is more common with in situ disease [34]. 
There are other histological types of breast carcinoma, such as tubular carcinoma, mutinous 
carcinoma, inflammatory breast cancer, invasive micropapillary carcinoma, metaplastic carcinoma, 
cystic adenoid carcinoma, and medullary carcinoma [31,35]. 
 
2.2.5 Breast Cancer Subtypes 
Gene expression studies have identified several distinct breast cancer subtypes. These 
include two main subtypes of estrogen receptor (ER)-negative tumors, basal-like and human 
epidermal growth factor receptor-2 (HER2)-enriched, and two subtypes of ER-positive tumors, 
luminal A and luminal B. These subtypes differ markedly in prognosis and in the therapeutic targets 
they express [36-38]. 
There are five main intrinsic or molecular subtypes of breast cancer that are based on the 
genes a cancer expresses, which are presented in Table 1:  
 
 
 
 
 
 
 17 
 
 
Table 1: Breast cancer’s molecular subtypes (adapted from [39-43]). 
Molecular subtypes 
of breast cancer 
IHC status Description 
 
 
 
Luminal A 
 
 
 
[ER+ and/or PR+]   
HER2- 
It corresponds to around 54% of all breast cancers. Luminal 
tumors respond well to hormone therapy but poorly to 
conventional chemotherapy and luminal A tumors could be 
adequately treated with endocrine therapy. It is hormone-
receptor positive (estrogen-receptor and/or progesterone-
receptor positive), HER2 negative, and has low levels of the 
protein Ki-67, which helps control how fast cancer cells grow. 
Luminal A cancers are low-grade, tend to grow slowly and 
have the best prognosis of all breast cancer subtypes. 
 
 
Luminal B negative 
HER2 
Luminal B positive 
HER2 
 
 
[ER+ and/or PR+]   
HER2- 
[ER+ and/or PR+]   
HER2+ 
It is hormone-receptor positive (estrogen-receptor and/or 
progesterone-receptor positive), and either HER2 positive or 
HER2 negative with high levels of Ki-67. Luminal B cancers 
generally grow slightly faster than luminal A cancers, and their 
prognosis is slightly worse. The risk of early relapse is high and 
it has greater resistance to therapy. Most luminal B cancers 
have high Recurrence Scores. 
 
 
 
HER2 over-
expression 
 
 
 
[ER- and PR-]   
HER2+ 
Correspond to 10-15% of all breast cancers, shows high 
expression of the HER2 and proliferation gene clusters and low 
expression of the luminal cluster. In fact it is hormone-receptor 
negative (estrogen-receptor and progesterone-receptor 
negative) and HER2 positive. HER2-enriched cancers tend to 
grow faster than luminal cancers and can have a worse 
prognosis, but they are often successfully treated with targeted 
therapies aimed at the HER2 protein.  
 
 
 
 
Basal-like 
 
 
 
 
[ER- and PR-]   
HER2- 
Its designation is due to some similarity in expression to that of 
the basal epithelial cells. Corresponds to about 15-20% of 
breast cancers. It is characterized by low expression of the 
luminal and HER2 gene clusters, hence being hormone-
receptor negative (estrogen-receptor and progesterone-
receptor negative) and HER2 negative, being called Triple-
negative. This type of cancer is more common in women 
with BRCA1 gene mutations, a gene responsible for tumor 
suppression. This  type of cancer is more common in the 
premenopausal years and among Afro-American women. It 
carries a poor prognosis. 
 
 
Normal-like 
 
 
[ER+ and/or PR+]   
HER2- 
It is similar to luminal A: hormone-receptor positive (estrogen-
receptor and/or progesterone-receptor positive), HER2 
negative, and with low levels of the protein Ki-67. Still, while 
normal-like breast cancer has a good prognosis, its prognosis 
is slightly worse than luminal A cancer’s. 
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2.2.6 Histological grade 
      Histological tumor grade has become an indicator of prognosis in breast cancer. It is based 
upon the degree of differentiation of the tumor tissue, on how abnormal the tumor cells are and 
how the tumor tissue looks like under a microscope [44]. 
It indicates how quickly a tumor is growing and spreading. If the cells of the tumor are close to 
normal cells and tissue architecture, the tumor is called “well-differentiated” and tends to grow and 
spread slowly. On the other hand, “undifferentiated” tumors have abnormal-looking cells and may 
lose normal tissue structures. Considering these differences in microscopic appearance, a 
numerical “grade” is assigned to most cancers [45,46]. 
This system to grade breast tumors based upon the following features: 
 tubule formation: how much of the tumor tissue has normal breast (milk) duct structures; 
 nuclear grade: an evaluation of the size and shape of the nucleus of the tumor cells; 
 mitotic rate: number of dividing cells, which is a measure of how fast the tumor cells are 
growing and dividing. 
Each category gets a score between 1 and 3 (“1” means the cells and tumor tissue look 
normal, “3” means the cells and tissue look abnormal). The scores for the three categories are then 
added, reaching a total score of 3 to 9. Three grades are possible (Table 2) [47,48]. 
Table 2: Scarff-Bloom-Richardson grade system (adapted from [47,48]). 
Grade Description Score 
Grade 1 The lowest grade, with well-differentiated breast cells that appear normal and 
are not growing fast; cancer is arranged in small tubules. 
3,4,5 
Grade 2 An intermediate grade, with moderately-differentiated breast cells. 6,7 
Grade 3 The highest grade, with poorly differentiated breast cells, that do not appear 
normal and tend to grow and spread more aggressively. 
8,9 
 
2.2.7 Staging 
Cancer stage refers to the size and extent of the primary tumor and whether or not cancer 
cells have spread in the body. Cancer stage is based upon factors like the tumor size (T), the 
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spread of cancer to nearby lymph nodes (N), and the number of tumors present (number of 
metastasis)(M) [49]. 
The staging system used for breast cancer is the TNM staging system, which combines the 
three factors [49]. 
The breast cancer TNM classification is reported in Tables 3 to 5: 
Table 3: Tumor (T) classification according to the American Joint Committee on Cancer Definition of Primary 
Tumor (adapted from [50 -52]). 
 
Table 4: Nodes (N) classification according to the American Joint Committee on Cancer Definition of 
Regional Lymph Nodes (adapted from [50-52]) 
Node category Node criteria 
NX The lymph nodes can not be assessed (for example, if they were previously 
removed). 
N0 There are64no cancer cells in any nearby nodes (no regional lymph node 
metastasis). 
ITCs (Isolated 
Tumor Cells) 
 
Small clusters of cancer cells less than 0.2 mm across or a cluster of fewer than 200 
cells in one area of a lymph node (lymph nodes containing only isolated tumor cells 
are not accounted as positive lymph nodes). 
N1   Micrometastasis or metastasis in 1‐3 axillary lymph nodes, but the nodes are not 
stuck to surrounding tissues. 
N1mi One or more lymph nodes contain areas of cancer cells called micrometastasis that 
are larger than 0.2mm, or the nodes contain more than 200 cancer cells but are less 
than 2 mm in total size. 
N2 There are cancer cells in the lymph nodes of the axilla, which are stuck to each other 
and to other structures (metastasis in 4‐9 axillary lymph nodes). 
N3 The cancer has spread to 10 or more axillary lymph nodes, or it has spread to the 
lymph nodes located under the clavicle, or above the superclavicular lymph nodes. 
The tumor may have also spread to the internal mammary lymph nodes. 
Tumor category Tumor criteria 
TX Primary tumor cannot be assessed. 
T0  No evidence of primary tumor. 
Tis Tumor is present only in ducts or lobules (in situ) of the breast tissue and has not 
spread into the surrounding tissue of the breast. 
T1 Tumor ≤ 2 cm in the greatest dimension. 
T2 Tumor > 2 cm but ≤ 5 cm in the greatest dimension. 
 T3 Tumor > 5 cm in the greatest dimension 
T4 Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration 
or macroscopic nodules) 
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Table 5: Metastasis (M) classification according to the American Joint Committee on Cancer Definition of 
Metastasis (adapted from [50-52]). 
Metastasis category Metastasis criteria 
M0 There is no sign that the cancer has spread (no evidence of distant metastasis). 
Mo(i+) There is no sign of cancer on physical examination, scans or x-rays. Neverthless, 
cancer cells are present in blood, bone marrow, or lymph nodes far away from 
the breast cancer – the cells are found by laboratory tests. 
M1 The cancer has spread to another part of the body (distant metastasis larger than 
0.2 mm are detected). 
 
The combination of the different variants of T, N and M determines the clinical stages. The 
stage provides a common way of describing the cancer, allowing doctors to plan the best 
treatments. There are 5 stages: stage 0, which is noninvasive carcinoma in situ, and stages I 
through IV, which are used for invasive breast cancer (Table 6). 
Table 6: Classification of breast cancer stages (adapted from [52-56]). 
Stage Prognostic 
groups 
Description 
Stage 0 Tis, N0, M0 Carcinoma is only in the ducts and lobules (in situ) of the breast 
tissue and has not spread to the surrounding tissue of the breast. 
It is also called noninvasive cancer. 
Stage I Stage IA T1, N0, M0 The tumor is small (< 2 cm), invasive, but has not spread yet to 
the lymph nodes. 
Stage IB T0 or T1, N1mi, 
M0 
Cancer has spread to the lymph nodes and the cancer in the 
lymph node is between 0.2 mm to 2 mm in size. There is either 
no evidence of a tumor in the breast or the tumor is ≤ 2 cm. 
 
 
Stage II 
Stage IIA T0 or T1 or T2, 
N0 or N1, Mo 
[T0, N1, M0]: there is no evidence of a tumor in the breast, 
but the cancer has spread to 1 to 3 axillary lymph nodes. 
[T1, N1, M0]: the tumor is ≤ 2 cm and has spread to the 
axillary lymph nodes. 
[T2, N0, M0]: the tumor is between 2 cm and 5 cm and has 
not spread to the axillary lymph nodes. 
Stage IIB T2 or T3, N0 or 
N1, M0 
[T2, N1, M0]: the tumor is between 2 cm and 5 cm and has 
spread to 1 to 3 axillary lymph nodes. 
[T3, N0, M0]: the tumor is > 5 cm but has not spread to the 
axillary lymph nodes. 
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Table 7: Classification of breast cancer stages (cont.) (adapted from [52-56]). 
Stage Prognostic 
groups 
Description 
 
 
 
Stage 
III 
Stage IIIA T0 to T3, N1 or 
N2, M0 
[T0,T1,T2 or T3,N2,M0]: the cancer of any size has spread to 4 
to 9 axillary lymph nodes or to internal mammary lymph nodes, 
but not to other parts of the body. 
[T3, N1, M0]: the tumor is > 5 cm and has spread to 1 to 3 
axillary lymph nodes. 
Stage IIIB T4, N0 to N2, 
M0 
The tumor has spread to the chest wall or caused ulceration of 
the breast or is diagnosed as inflammatory breast cancer. It may 
or may not have spread to up to 9 axillary or internal mammary 
lymph nodes. 
Stage IIIC Any T, N3, M0 A tumor of any size that has spread to 10 or more axillary lymph 
nodes, the internal mammary lymph nodes, and/or the lymph 
nodes under the collarbone.  
Stage IV Any T, any N, 
M1 
The tumor can be of any size and has spread to other organs, 
such as bones, lungs, brain, liver, distant lymph nodes, or chest 
wall. 
Recurrent  Recurrent cancer is a cancer that has come back after treatment, 
and can be described as local, regional, and/or distant. 
 
2.2.8 Risk factors 
The increased risk for the development of female breast cancer is associated with age, 
reproductive factors, personal or family history of breast disease, genetic pre-disposition and 
environmental factors [57,58]. 
In fact, the risk of developing breast cancer increases with age: by using the SEER6 database, 
the probability of a woman developing breast cancer is 1: 202 from birth to 39 years of age, 1:26 
from 40-59 years, and 1:28 from 60-69 years [57,58].  
A personal history of breast cancer or some breast disease are also significant risk factors for 
the development of a breast cancer or a second breast cancer [57,58].  
Genetic predisposition alleles have been described in terms of clinical significance, conferring 
a 40%-85% lifetime risk of developing breast cancer [57,58]. 
                                                          
6
 SEER – Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. 
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A person lifestyle also influences the risk of breast cancer. Lifestyle factors include the 
excessive use of alcohol, obesity and physical inactivity. Consistent physical activity has been 
shown to reduce the risk of breast cancer conferring a 2-5% decrease of the risk [57,58].   
Environmental factors are, for example, radiation exposure from various sources including 
medical treatment, and they increase the risk of breast cancer due to gene mutations [57,58].   
 
2.2.9 Epidemology 
      Breast cancer is the most common cancer in women worldwide after skin cancer. It represents 
16% of all cancers in women [59,60].  
Worldwide, there were about 2.1 million newly diagnosed female breast cancer cases in 2018. 
The disease is the most frequently diagnosed cancer in the vast majority of the countries and it is 
also the leading cause of cancer death in over 100 countries [59,60].  
All around the world the incidence of this cancer shows varied rates. These rates are low in 
less-developed countries and higher in the more-developed countries [59,60].  
The average age at diagnosis is usually around 60 (Figure 10). The trend reflects a 
combination of demographic, social and economic development, including greater levels of obesity, 
physical inactivity, and increases in breast cancer screening and awareness. The primary risk 
factors for breast cancer are not easily modifiable since they derive from prolonged hormonal 
exposures [60]. 
 
Figure 10: Breast cancer age-standardized incidence rate per 100.000 (retrieved from [59]). 
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2.2.10 Breast cancer treatment 
Typically, treatment plans are based upon the type of breast cancer; its biology, behavior, and 
stage; the presence of known gene mutations; the patient’s age; general health and other health  
conditions and personal preferences. In general, the more the breast cancer has spread, the more 
treatment you will likely need [61,62]. 
There are two types of treatments: local treatments, in which the tumor is treated without 
affecting the rest of the body, and systemic therapies, which use different drugs (chemotherapy, 
hormone therapy, targeted therapy) which will affect the whole body (Table 7) [61,62]. 
Table 8: Treatment of Breast Cancer by Stage (adapted from [63,64]). 
Stage  Therapeutic options 
Stage 0 Surgery: lumpectomy or mastectomy. 
Radiation therapy: after the surgery, the radiation attacks any abnormal cells that might have been 
missed. 
Hormone therapy : if the DCIS is hormone receptor-positive (HR+), this therapy  may also help 
prevent more cancer from developing.  
Stage I Surgery: mastectomy or lumpectomy. 
Radiation therapy: necessary after lumpectomy. 
Hormonal therapy: prescribed for patients with hormone-receptor-positive (ER+) cancer. 
Target therapy: treat cancers that are HER2-positive (HER2+). 
Chemotherapy: to reduce the risk of recurrence. 
Stage II Surgery: mastectomy or lumpectomy. 
Radiation therapy: after surgery. 
Hormonal therapy: prescribed for patients with hormone-receptor-positive (ER+) cancer. 
Target therapy: treat cancers that are HER2-positive (HER2+). 
Chemotherapy: recommended. 
Stage III Surgery: total mastectomy.  
Radiation therapy: after surgery. 
Hormonal therapy: prescribed for patients with hormone-receptor-positive (ER+) cancer. 
Target therapy: treat cancers that are HER2-positive (HER2+). 
Chemotherapy: almost always recommended, necessary to reduce the cancer and/or treat 
cancer in the lymph nodes. 
Stage IV Surgery: total mastectomy. 
Radiation therapy: after surgery. 
Hormonal therapy: prescribed for patient with hormone-receptor-positive (ER+) cancer. 
Target therapy: treat cancers that are HER2-positive (HER2+) or cancers that are HER2-
negative but have a BRCA1 or BRCA2 mutation. 
Chemotherapy: almost always recommended. 
Recurrent  Treatment for recurrent breast cancer depends on where the cancer recurs and what 
treatments the patient has had before. 
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The most common surgical procedures are lumpectomy and total mastectomy. In the first one 
only the abnormal cells and some breast tissue are removed, while in the second one the entire 
breast is removed [63]. 
Radiotherapy is a technique that uses radiation to destroy cancer cells. Although radiation also 
damages normal cells, cancer cells are especially sensitive to its effects. This is a localized 
treatment, which means it only treats the area of the body it is aimed at. It is used as integral part 
of the breast cancer treatment, being usually applied after surgery. Its aim is to destroy any 
remaining cancer cells, reduce the recurrence and increase the possibility of survival. 
Radiotherapy can also be used before the surgery to reduce the size of the tumor, making it easier 
to be removed [64-67]. 
 
Chemotherapy (also called “chemo”) is a treatment which uses cytotoxic drugs, administered 
orally or intravenously, in order to kill cancer cells. It is a systemic therapy, which means it affects 
the whole body by going through the bloodstream. It can also affect some fast-growing healthy 
cells, like those of the skin, hair, intestines, and bone marrow. This is what causes some of the 
side effects from the treatment. Usually chemotherapy is used after surgery to reduce the risk of 
the cancer coming back, but, in some cases, it is given before surgery to reduce the cancer 
dimensions [68,69]. 
The drugs are different and are named according to their action or origin. In many cases, 
chemotherapy medicines are given in combination, which means the patient gets two or three 
different medicines at the same time (Table 8) [70]. 
Chemotherapy drugs attack all cells that are growing quickly (including cancer cells), so 
researchers have developed new types of drugs that target some of these cell changes. These 
targeted drugs are designed to block the growth and spread of cancer cells only. Targeted drugs 
sometimes work even when chemo drugs do not, can help other types of treatment to work better 
and have different side effects than chemo [68,69]. 
There are targeted therapies for HER2-positive breast cancer, for hormone receptor-positive 
breast cancer, for cancers with aPIK3CA gene mutation, and for women with BRCA gene 
mutations [71-73]. 
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Table 9: Chemotherapy drugs for breast cancer (adapted from [70]) 
Class  Chemical name Description 
Anthracyclines   Doxorubicin 
Epirubicin 
Daunorubicin 
Mitoxantrone 
Chemically similar to antibiotics, they damage the genetic material 
of cancer cells, which induces the cells dead. They are given 
intravenously. 
Alkylating 
agents 
Cyclophosphamid Weaken or destroy breast cancer cells by damaging the cells’ 
genetic material. They can be taken orally as a pill or given 
intravenously. 
Antiangiogenesi
s targeted 
therapy 
Bevacizumab  Blocks the growth of new blood vessels into a tumor, choking off 
the blood supply to cancer cells. It is given intravenously. 
Antimetabolites Fluorouracil 
Gemcitabine 
Methotrexate 
Capecitabine 
Kill breast cancer cells by inhibiting enzymes involved in the 
synthesis of DNA and proteins, leading to cancer cell dead as it 
gets ready to divide. They are given intravenously, except 
Capecitabine which is taken orally as a pill. 
Antitumor 
antibiotic 
Mutamycin kill cancer cells by damaging their genes and interfering with their 
re production. It is given intravenously. 
Erythropoiesis 
stimulating 
agents 
Epoetin alfa 
Darbepoetin alfa 
Cause extra red blood cells production by the bone marrow, They 
are used to treat anemia that can be caused by chemotherapy. 
They are given intravenously or as an injection 1 to 3 times per 
week. 
mTOR 
(mammalian 
target of 
rapamycin) 
inhibitor 
Everolimus mTOR is a kinase, a type of protein in the body that helps all cells 
(healthy and cancer cells) to get the energy they need, hence they 
help certain breast cancers grow. mTOR inhibitors work by 
interfering with the mTOR kinase. It is a pill taken orally, usually 
daily.  
Platinum-based Carboplatin It weakens or destroys breast cancer cells by damaging the 
genetic material and making it hard for cells to repair any genetic 
damage. 
Taxanes Paclitaxel 
Docetaxel 
 
Interfere with the ability of cancer cells to divide. They act by 
inhibiting cell mitosis: bind specifically to the microtubule’s tubulin 
and prevent its depolymerization. The result is a significant 
decrease in free tubulin necessary for the formation of 
microtubules, with consequent arrest of cellular mitosis. They are 
given intravenously. 
Vinca alkaloids Vincristine 
Vinorelbine 
Kill cancer cells by interfering with genes and stopping the cells 
from reproducing themselves. They are given intravenously. 
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2.3 Colon Cancer 
Worldwide, colon cancer is the third most common type of cancer and it affects men and 
women almost equally. It affects about 140,000 people every year, mainly people over 40 years 
old, being the leading signs of colon cancer bleeding and changes to bowel habits [74]. 
Colon cancer is the malignant tumor of the large intestine, the result of the uncontrolled 
proliferation of one of the cells present in the layers of the inner wall of the large intestine. It 
develops from a "mad cell", located in the inner wall of one of the anatomical parts of the colon: 
ascending, transverse or descending colon, sigmoid or rectum [74-75].  
The most common localization of colon cancer is the rectum (about 50% of cases), followed by 
the sigmoid (19-21% of cases), ascending colon (16%), transverse colon (8%) and descendant 
colon (6% of cases) [74-75]. 
The most common type of colon and rectal cancer is adenocarcinoma of the colon (95% of all 
cases). In the gastrointestinal tract, rectal and colon adenocarcinomas develop in the cells that are 
inside the large intestine. Types of colorectal cancer less common are primary colorectal 
lymphoma, gastrointestinal stromal tumors, leiomyosarcomas, carcinoid tumors and melanomas 
[74-75]. 
 
2.3.1 Anatomy of the Colon 
      The colon is the terminal portion of the digestive tract. It is shorter and with a larger diameter 
than the small intestine. It absorbs water, salt and some essential fat-soluble vitamins, before they 
are eliminated by the body [75,76].  
The colon is divided into four sections: ascending colon, transverse colon, descending colon, 
and sigmoid (Figure 11) [76].  
 
Figure 11: Colon anatomy (retrieved from [77]) 
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2.3.2 Colon cancer grading and staging 
      The grade gives doctors an idea of how quickly a cancer may develop, while the stage of a 
cancer is how big it is and whether it has spread [78]. 
The grading system is the same one used for breast cancer [78-81]:  
 grade 1 (low-grade): the cancer cells tend to grow slowly and look similar to normal cells 
(well differentiated); 
 grade 2 (moderate-grade): the cancer cells look more abnormal; 
 grade 3 (high-grade): the cancer cells tend to grow more quickly and look very abnormal 
(poorly differentiated). 
The staging system for colon cancer follows the tumor/node/metastasis (TNM) system of the 
American Joint Committee on Cancer (AJCC) [78-81]. 
“T” stands for the size of the tumor: how far the cancer grew into the wall (mucosa, 
submucosa, muscularis propria, subserosa and serosa) of the colon (Table 9) [78-81]. 
“N” stands for the spreading to nearby lymph nodes (Table 10) [78-81]. 
“M” stands for the spreading metastasis to distant sites, like lymph nodes or distant organs 
such as the liver or lungs (Table 11) [78-81]. 
 
Table 10: Primary tumor (T) (adapted from [78-81]). 
Tumor 
category 
Description 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ (intraepithelial or 
intramucosal carcinoma) 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades through the muscularis 
propria into the pericolorectal tissues 
T4 Tumor invades the visceral peritoneum or 
invades or adheres to adjacent organ or 
structure 
T4a Tumor invades through the visceral 
peritoneum 
T4b Tumor invades or is adherent to other 
organs  
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Table 11: Lymph nodes (N) (adapted from [78-81]). 
Node 
category 
Description 
NX Regional lymph node cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastasis in 1-3 regional lymph nodes 
(tumor ≥ 0.2 mm) or any number of tumor 
deposits (in the subserosa or in the 
perirectal tissues) are present and all 
identifiable nodes are negative. 
N1a Metastasis in 1 regional lymph node. 
N1b Metastasis in 2-3 regional lymph nodes. 
N1c Tumor in the subserosa or in the perirectal 
tissues without regional metastasis. 
N2 Metastasis in 4 or more regional lymph 
nodes. 
N2a Metastasis in 4-6 regional lymph nodes. 
N2b Metastasis in 7 or more regional lymph 
nodes. 
 
Table 12: Metastasis (M) (adapted from [78-81]). 
M category Description  
M0 No distant metastasis, no evidence of tumor 
in distant sites or organs. 
M1 Metastasis to one or more distant organs, or 
peritoneal metastasis.  
M1a Metastasis confined to 1 organ, without 
peritoneal metastasis. 
M1b Metastasis to 2 or more organs, without 
peritoneal metastasis. 
M1c Metastasis to the peritoneal surface, alone or 
with organ metastases. 
 
The combination of the different variants of T, N and M determines the clinical stages 
(Table 12) [78-81]. 
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Table 13: Colon cancer stages (adapted from [78-81]). 
Stage Prognostic groups Description 
Stage 0 Tis, M0, N0 The earliest stage, known as carcinoma in situ or 
intramucosal carcinoma (Tis), it has not grown beyond 
the mucosa of the colon or rectum. 
Stage I T1 or T2, N0, M0 The cancer has grown through the mucosa into the 
submucosa (T1), and it may also have grown into the 
muscularis propria (T2). It has not spread to nearby 
lymph nodes (N0) or to distant sites (M0). 
Stage II  Stage IIA T3, N0, M0 The cancer has grown into the layers of the colon or 
rectum (has not gone through them) (T3), it has not 
reached nearby organs (M0) neither spread to nearby 
lymph nodes (N0). 
Stage IIB T4a, N0, M0 The cancer has grown through the wall of the colon or 
rectum (T4a) but it has not yet spread to nearby lymph 
nodes (N0) or to distant sites (M0). 
Stage IIC T4b, N0, M0 The cancer has grown through the wall of the colon or 
rectum and has grown into other nearby tissues or 
organs (T4b), but it has not yet spread to nearby lymph 
nodes (N0) or to distant sites (M0). 
Stage III Stage IIIA T1 or T2, N1, M0  
 
The cancer has grown into the submucosa (T1), and it 
may also have grown into the muscularis propria (T2). It 
has spread to 1 to 3 nearby lymph nodes (N1), and it 
has not spread to distant sites (M0). 
T1, N2a, M0 The cancer has grown into the submucosa (T1), it has 
spread to 4 to 6 nearby lymph nodes (N2a), but it has 
not spread to distant sites (M0). 
Stage IIIB T3, N1/N1c, M0 The cancer has grown into the layers of the colon or 
rectum (T3), it has spread to 1 to 3 nearby lymph nodes 
(N1) or into areas of fat near the lymph nodes but not 
the nodes themselves (N1c). It has not spread to distant 
sites (M0). 
T2 or T3, N2a, M0 The cancer has grown into the muscularis propria (T2) 
or into the layers of the colon or rectum (T3). It has 
spread to 4 to 6 nearby lymph nodes (N2a), but it has 
not spread to distant sites (M0). 
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Table 14: Colon cancer stages (cont.) (adapted from [78-81]). 
Stage Prognostic groups Description 
Stage III Stage IIIC T1 or T2, N2b, M0 The cancer has grown into the submucosa (T1), and it 
may also have grown into the muscularis propria (T2). It 
has spread to 7 or more nearby lymph nodes (N2b), but 
it has not spread to distant sites (M0). 
T4a, N2a, M0 The cancer has grown through the wall of the colon or 
rectum (and the visceral peritoneum) but has not 
reached nearby organs (T4a). It has spread to 4 to 6 
nearby lymph nodes (N2a), but it has not spread to 
distant sites (M0). 
Stage IV  
 
Stage IVA 
Stage IVB 
T3 or T4a, N2b, M0 The cancer has grown into the layers of the colon or 
rectum (T3) or through the visceral peritoneum (T4a) but 
has not reached nearby organs. It has spread to 7 or 
more nearby lymph nodes (N2b). It has not spread to 
distant sites (M0). 
T4b, N1 or N2, M0 The cancer has grown through the wall of the colon or 
rectum and has grown into other nearby tissues or 
organs (T4b). It has spread to at least one nearby lymph 
node or into areas of fat near the lymph nodes (N1 or 
N2). It has not spread to distant sites (M0). 
Any T, any N, M1a The cancer may or may not have grown through the wall 
of the colon or rectum (Any T). It might or might not 
have spread to nearby lymph nodes. (Any N). It has 
spread to 1 distant organ (such as the liver or lung) or 
distant set of lymph nodes (M1a). 
 
Stage IVC 
 
Any T, any N, M1b The cancer might or might not have grown through the 
wall of the colon or rectum (Any T). It might or might not 
have spread to nearby lymph nodes (Any N). It has 
spread to more than 1 distant organ (such as the liver or 
lung) or distant set of lymph nodes (M1b). 
Any T, any N, M1c The cancer might or not have grown through the wall of 
the colon or rectum (Any T). It might or might not have 
spread to nearby lymph nodes (Any N). It has spread to 
distant parts of the peritoneum (the lining of the 
abdominal cavity), and may or may not have spread to 
distant organs or lymph nodes (M1c). 
 
2.3.3 Colon cancer pathogenesis 
Colon cancer is a disease originating from the epithelial cells lining the colon of the 
gastrointestinal tract. One of the central aspects of colon cancer formation is the accumulation of 
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acquired genetic and epigenetic changes that transform normal glandular epithelial cells into 
invasive adenocarcinomas. The polyp to cancer progression sequence involves a step that initiates 
the formation of benign neoplasms; followed by a step that promotes the progression to more 
histologically advanced neoplasms; and then a step that transforms the tumors to invasive 
carcinoma (Figure 12) [82-85]. 
Genomic and epigenomic instability contribute to the formation of colorectal cancers. Some 
major forms of instability include [86]: 
 chromosomal instability (CIN), 
 microsatellite instability (MSI), 
 non-MSI hypermutability, 
 global DNA hypomethylation. 
 
Figure 12: Schematic diagram of polyp --> colorectal cancer sequence (retrieved from [86]).  
  
2.3.4 Risk factors 
The risk of getting colorectal cancer increases with age, in fact more than 90% of cases occur 
in people who are 50 years old or older [87]. 
 
Other risk factors include having some inflammatory bowel disease, like Crohn’s disease or 
ulcerative colitis, or other health problems such as type 2 diabetes or an inherited syndrome, 
causing gene changes (mutations) [87,88]. 
Another important point to take into account is the patient’s family history: nearly 1 in 3 people 
who develop colorectal cancer have other family members who have had it [87,88].  
People with a history of colorectal cancer in a first-degree relative (parent, sibling, or child) are 
at increased risk. The reasons for the increased risk are not clear in all cases. Cancers can 
“appear in the family” due to inherited genes, shared environmental factors, or some combination 
of these [87,88]. 
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Lifestyle factors may also contribute to an increased risk of colorectal cancer. In fact, physical 
inactivity, an high-fat and low-fiber diet which is low in fruit and vegetables, an obesity condition, 
alcohol consumption and the use of tobacco very probably contribute to the increased risk of colon 
cancer [87,88]. 
Another thing influencing colon cancer risk is the race: Afro-Americans, for example, are more 
likely than other U.S. racial and ethnic groups to get colorectal cancer, however, the reason for this, is 
unknown [87,88]. 
 
2.3.5 Epidemology 
Colorectal cancer is a major cause of morbidity and mortality throughout the world, accounting 
for over 9% of all cancer incidence. It is the third most commonly diagnosed cancer both in men 
and women. One in 22 men and one in 24 women will be diagnosed with colorectal cancer during 
their lifetime. There were over 1.8 million new cases in 2018 [89,90]. 
There is a large geographic difference in the global distribution of colorectal cancer. Colorectal 
cancer is mainly a disease of developed countries with a western culture worldwide mortality 
attributable to colorectal cancer of approximately half of the incidence [89-91]. 
The highest colon cancer incidence rates are found in parts of Europe, Australia and New 
Zealand, Northern America, and Eastern Asia (Figure 13) [89-91]. 
                                      
Figure 13: Colorectal cancer worldwide (retrieved from [92]). 
 
2.3.6 Colon cancer treatment 
The treatment plan for colorectal cancer does not include a perfectly standardized design, it 
must be modified and adjusted depending on the patient, considering the extent of the tumor and 
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its proliferation, as well as the risks it can pose to the patient's health, taking also into account 
other possible pathologies of the patient and any co-therapies already in progress. In this 
perspective, each patient must be considered as a unique case. Cancer treatment can include 
surgery, radiotherapy and/or chemotherapy. In most cases a combined pre and post-surgical 
therapy is performed depending on the patient. Drug combinations usually work better than single 
drugs since different drugs kill cancer cells in different ways (Table 13) [93,94]. 
Table 15: Treatment of colon cancer by stage (adapted from [93,94]). 
Stage  Therapeutic options 
Stage 0 Surgery: local excision or simple polypectomy. If the tumor is too large to remove by local excision, 
resection and anastomosis are performed. 
Stage I Surgery: resection and anastomosis. 
Stage II Surgery: resection and anastomosis. 
Chemotherapy: to reduce the risk of recurrence. 
Stage III Surgery: resection and anastomosis. 
Chemotherapy: recommended. 
Stage IV Surgery: resection and anastomosis. 
Radiation therapy: for patient who cannot have surgery or as palliative therapy. 
Chemotherapy: before surgery to shrink the tumor, after surgery, or both. 
Recurrent  Treatment for recurrent colon cancer depends on where the cancer recurs (local excision, 
removal of parts of organs where the cancer has spread, chemotherapy and radiotherapy) and 
what treatments the patient has had before 
 
Radiotherapy for colon cancer is less used than in other types of cancer. In fact, here are two 
major limitations regarding colon cancer: a poorly defined target (since colon is mobile), and the 
fact that dose-limiting structures surround the colon (i.e., large amount of small bowel, kidney, and 
liver) [95,96]. 
During the practical work resulting in the present thesis, some of the chemotherapeutical drugs 
were used according to the chemo strategies used in clinics (Table 14). 
The chemo and radiotherapy protocols are increasingly specific for cancer cells, but they are 
each time less effective due to the chemo/radio resistance that individuals acquire [97]. 
Taking this into account, it is necessary to make people understand from young ages and at 
the level of education and family system, that lifestyle alterations help to prevent this dreadful 
pathology. The focus of several studies is on the use of alternative agents/helpers present in 
various plants, extracts or infusions, which are able to prevent or delay the onset, development and 
progression of the disease. The aim of these studies is to analyze the efficacy and limitations both 
in in vitro and in vivo tests. 
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Table 16: Applied chemotherapy drugs for colon cancer according to the chemo strategies used in clinics 
(adapted from [98,99]). 
Regimen Drug/Drug 
Combination 
Dosages Description 
OX Oxaliplatin Oxaliplatin: 130 mg/m
2
 IV in D1. 
Repeat the cycle every day for 21 days. 
OX is used when colon cancer 
is in an advanced stage and as 
adjuvant therapy in patients 
who have had surgery. 
5-FU 5-Fluorouracil 5-Fluorouracil: 1000 mg/m
2
/day IV 
continuous from D1 to D5. 
Repeat the infusion in cycles 1 and 5 of 
chemotherapy. 
5-FU is used when colon cancer 
is in an advanced stage and in 
combination with other drugs. 
IRI Irinotecan Irinotecan: 350 mg/m
2
 IV in 90 min. 
Repeat the cycle every 21 days. 
IRI is used when colon cancer 
has metastasized or has not 
gotten better with other 
chemotherapy. 
CAP Capecitabine Capecitabine: 1250 mg/m
2 
VO 2 times per 
day, from D1 to D14. 
Repeat the cycle every 21 days, for 8 
cycles in total. 
CAP is used to treat stage III 
colorectal cancer in patients 
who have had surgery to 
remove the cancer and to treat 
patients ith metastatic colorectal 
cancer. 
CET Cetuximab Cetuximab: initial dose 400 mg/m
2
 IV in 2 h, 
followed by 250 mg/m
2
 IV in 1 h weekly. 
CET is used in patient in which 
cancer has metastasized and 
when cancer did not respond 
to oxaliplatin and irinotecan.  
FOLFOX 5-Fluorouracil 
+  Leucovorin 
+ Oxaliplatin 
Oxaliplatin: 100 mg/m
2
 in 2 h in D1. 
Calcium folinate: 400 mg/m
2 
IV in D1 with 2 
h infusion. 
5-Fluorouracil: 400 mg/m
2 
IV in D1, followed 
by 2400 mg/m
2 
IV continuous for 46 h in D1 
and D2. 
Repeat the cycle every 14 days, for 12 
cycles. 
FOLFOX is a combination of 
drugs, used when cancer is in 
an advanced stage.  
FOLFIRI 5-Fluorouracil 
+  Leucovorin 
+ Irinotecan 
Irinotecan: 180 mg/m
2
 IV in 90 min in D1. 
Calcium folinate: 400 mg/m
2 
IV in D1 with 2 
h infusion, before fluorouacil. 
5- Fluorouracil: 400 mg/m
2 
IV in D1, 
followed by 2400 mg/m
2 
IV continuous for 
46 h. 
Repeat the cycle every 14 days. 
FOLFIRI is used when cancer is 
in an advanced stage. 
CAPOX Capecitabine + 
Oxaliplatin 
Capecitabine: 1000 mg/m
2 
VO 2 times per 
day, from D1 to D4. 
Oxaliplatin: 130 mg/m
2
 IV in 2 h in D1. 
Repeat the cycle every 21 days. 
CAPOX is used when cancer is 
in an advanced stage. 
CAPIRI Capecitabine + 
Irinotecan 
Capecitabine: 1000 mg/m
2 
VO 2 times per 
day, from D1 to D14, or from D2 to D15. 
Irinotecan: 250 mg/m
2
 IV in D1. 
Repeat the cycle every 21 days. 
CAPIRI is used when cancer is 
in an advanced stage. 
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2.4 In vitro model  
  2.4.1 MCF-7 cell line 
The breast cancer cells used for the realization of the present work was the MCF-7 cell line. 
This cell line has been bought from the American Type Culture Collection (ATCC) (ATCC® HTB-22™, 
Rockville, Md., USA), a unique private and nonprofit resource dedicated to the collection, 
preservation and distribution of authentic cultures of living microorganisms, viruses, DNA probes, 
plants, and human and animal cells.  
The MCF-7 cell line is a widely studied epithelial cancer cell line derived from breast 
adenocarcinoma, having the characteristics of differentiated mammary epithelium. 
MCF-7 cells are used for in vitro and in vivo breast cancer studies as they have the ability to 
process estrogen in the form of estradiol via estrogen receptors in the cell cytoplasm. In fact, 
MCF-7 is an estrogen receptor (ER) positive, a progesterone receptor positive and HER2 negative 
cell line. 
This cell line is noninvasive and represents an early-stage disease model. The breast cancer 
molecular subtype is Luminal A, specifically luminal A ductal carcinoma [100,101].  
 
MCF-7 cells were established in 1973 by Dr. Soule and colleagues at the Michigan Cancer 
Foundation (hence the name). This cell line was isolated in 1970 for laboratory studies from the 
pleural effusion of a 69-year-old woman with metastatic disease. The patient was diagnosed with a 
benign tumor on the right breast and was then operated by mastectomy 10 years before the 
primary cell culture was started. Afterwards, the patient was submitted to a consecutive radical 
mastectomy of her left breast due to a malignant adenocarcinoma 4 years later. Just after she 
completed post-operative chest wall radiotherapy, a local recurrence in her left chest area was 
noticed. The recurrence was controlled by radiation and hormone therapy for three years. The 
patient was probably treated with high doses of the hormone and the disease was controlled three 
times longer than expected, since the tumor was hormone-responsive [102-105].  
The cells from the pleural effusion grew initially in suspension and ultimately formed a 
monolayer on plastic, growing as a continuous culture. The popularity of the MCF-7 cell lines for 
breast cancer research reflects its fidelity to many aspects of breast cancer in the clinical setting, 
particularly in the management of postmenopausal women with hormone receptor–positive breast 
cancer [102-105].  
One of the most important contributions of the MCF-7 cell line to breast cancer research has 
been its utility for the study of the estrogen receptor (ER), as this cell line expresses substantial 
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levels of ER mimicking the majority of invasive human breast cancers that express ER. These cells 
also express androgen, progesterone, and glucocorticoid receptors and have been a valuable 
model system to elucidate pathways of hormone response and resistance [102,103]. 
It was demonstrated that an anti-estrogen substance inhibited the growth of MCF-7 cells but 
the inhibition could be reversed by estrogen. The central focus of past studies with this cell line 
was to prove that estrogen directly stimulated tumor growth and that it is a suitable model for 
breast cancer investigations worldwide, for both in vitro and in vivo studies [106,107]. 
 
 2.4.2 WiDr cell line 
The colon cancer cell line used for the realization of the present work was the WiDr cell line. 
The WiDr cell line (ATCC® CCL-218 ™) was originally isolated in 1971 as a colon 
adenocarcinoma and established from a 78-year-old woman. However, through the identification 
method of the deoxyribonucleic acid (DNA) footprint it was shown that this cell line was derived 
from the HT-29 cell line, established as adenocarcinoma of the human colon in 1964. The 
phenotypes for some isozymes were identical for HT-29 and WiDr cell lines [108-110]. 
The WiDr cell line is tumorigenic in nude mice and expresses the carcinoembryonic antigen 
(CEA), the colon-specific antigen (CSAp) and transforms the growth factor beta and the epidermal 
growth factor (EGF). The cells quantity increases almost logarithmically during the culture period, 
making it a useful biochemical marker in immunohistopathology. Moreover, it has a short 
duplication time, comparing to other cancer cell lines - around 15 hours - and a confluence 
efficiency of 51%, showing that it easily propagates in culture with adherent characteristics. This 
cell line, when inoculated in immunosuppressed animals, develops histologically confirmed tumors 
with great efficacy. It is a well characterized cell line and it is used in many cancer and 
carcinogenesis studies, both in in vitro and in vivo studies [110,111]. 
 
2.5 New approaches in the fight against cancer - 
natural metabolites 
Despite the progress made in the development of potent chemotherapy drugs, their toxicity to 
normal tissues and adverse side effects in multiple organ systems, as well as drug resistance, 
have remained the major obstacles for the successful clinical use. Cytotoxic agents decrease 
considerably the quality of life of cancer patients, manifested as acute complaints and also 
impacting on life of survivors for years after the treatment. Various plant-derived compounds 
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improve the efficiency of cytotoxic agents, decreasing their resistance, lowering and alleviating 
toxic side effects, and detoxifying the body of chemotherapeutics [112,113]. 
 
Microorganisms, plants, lichens, fungi and animals are able to produce a large quantity and 
variety of biologically active compounds, some of which have anticarcinogenic properties. In 
particular, plant metabolites exhibit a wide range of biological functions, including anti-cancer, 
analgesic, anti-inflammation, and anti-microbial activities and are emerging as new leads for anti-
cancer drug development.  
Bioactive compounds like polyphenols (flavonoids, stilbenes, phenolic acids), terpenoids 
(monoterpenoid, diterpenoids, tetraterpenoids), alkaloids and organosulfur compounds are 
secondary metabolites produced by different types of plants that are being studied regarding 
cancer treatment and prevention [114-116]. 
During the last few decades, a wide range of cytotoxic agents retrieved from plants, was 
chemically identified and their effectiveness in therapeutic cancer treatment was proved. Some 
compounds used in chemotherapy are vinca alkaloids (vinblastine, vincristine, vinorelbine, 
vinflunine), the taxanes (paclitaxel), and the camptothecin derivatives [114-116].  
Some phytochemicals derived from food have been shown to be able to affect the efficacy of 
traditional chemotherapeutic agents, increase the cytotoxic activity of several drugs and reduce 
inflammatory responses [114-116]. 
Polyphenol classes (flavonoids, phenolic acids, lignans and stilbenes) are another important 
type of natural agents with good anticarcinogenic efficacy, that have been studied both in vitro and 
in vivo for many years [117,118]. 
The anticancer efficacy of natural polyphenols has largely been attributed to their potent 
antioxidant and anti-inflammatory activities as well as their abilities to modulate molecular targets 
and signaling pathways, which were associated with cell survival, proliferation, differentiation, 
migration, angiogenesis, hormone activities, detoxification enzymes and immune responses 
[117,118]. 
In this work, green tea, a popular drink in Asia, was considered. Catechins from green tea, in 
fact, can increase the therapeutic effect of drug-resistant tumors in animal studies, and the 
administration of green tea increases the concentration of this chemotherapeutic agent in tumor 
but not in normal tissue, enhancing its antitumor activity [115-118]. 
These natural compounds appear to act by interfering in multiple cellular signaling pathways, 
activating cell death signals, inducing apoptosis of cancer cells and blocking key events of tumor 
initiation and promotion, thus reversing the premalignant stage, without affecting negatively normal 
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cells. These agents may also prevent tumorigenesis by inhibiting or retarding tumor progression or 
by promoting cell differentiation [117-120].  
The positive action of phytochemicals against tumors is described in the following figure 
(Figure 14). 
 
Figure 14: Carcinogenic process and phytochemicals effects (retrieved from [121]). 
 
2.5.1 Green Tea 
Tea, next to water, is the most popular beverage in the world. It is native of China and 
Southeast Asia and its plants have been cultivated for millions of years. Tealeaves were initially 
used as a medicine and later the tea became a drink [122].  
Tea is made from the leaf of the plant Camellia sinensis (Figure 15). After harvesting, tea 
leaves begin a process of fermentation which involves the oxidation of flavonoids present in the 
leaves, caused by release of intracellular polyphenol oxidase. During oxidation, chemicals in the 
leaves are broken down by enzymes, resulting in darkening of the leaves and defining the aroma 
of tea. This oxidation process can be stopped by heating, which inactivates the enzymes. The 
amount of oxidation and other aspects of processing determine a tea’s type [122,123].  
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Figure 15: Camellia sinensis (retrieved from [124]) 
Tea has been subjected to many scientific and medical studies to determine the extent of its 
long reported health benefits, as growing body of evidence from laboratory animal studies 
demonstrated that tea consumption has an inhibitory effect on carcinogenesis at different organ 
sites and tea drinkers may have a lower risk of developing heart disease and certain types of 
cancer [125].  
There are three different types of tea - black tea, oolong tea and green tea.  
The focus of this research is on green tea, which is made from unwilted leaves that are not 
oxidized, allowing the conservation of natural polyphenols, whose benefits for drinkers are highly 
studied in particular regarding the preventive effect on many pathological disorders [122,123;125]. 
Considering the chemical composition of tea, the list of components is large: polyphenols 
(30%), alkaloids (caffeine, theophylline and theobromine), amino acids (1-4% dry weight), fiber 
(26% dry weight), carbohydrates (5-7% dry weight), proteins (15-20% dry wight), lipids (5% dry 
weight), volatile organic compounds, fluoride, minerals and trace elements (5% dry weight) [126-
127]. 
The polyphenols, a large group of plant chemicals, include flavonoids, flavans and phenolic 
acids. Green tea has mainly flavonoids, called catechins, that are thought to be responsible for the 
health benefits that have traditionally been attributed to tea, especially green tea. In green tea 
there are 4 types of catechines: epigallocatechin gallate (EGCG), epigallocatechin (EGC), 
epicatechin gallate (ECG), and epicatechin (EC). One 200 mL cup of green tea supplies 140, 65, 
28, and 17 mg of these polyphenols, respectively. The most active and abundant catechin in green 
tea is epigallocatechin-3-gallate (EGCG) [125-127]. 
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Green tea polyphenols have been shown to have antioxidant properties against lipid 
peroxidation in phospholipid bilayers and in biological systems.  
The mechanisms by which tea polyphenols may act include inhibition of mutagenesis, 
genotoxicity,  transformation, cell proliferation, and angiogenesis. Each mechanism involves 
multiple potential molecular targets. Many studies have suggested that the polyphenol EGCG 
possesses the most potent antioxidative activity against all stages of multistage carcinogenesis 
[128]. 
The consumption of green tea is associated with a lower risk of cancer due to its important role 
in the reduction of free radicals that are capable of causing damage to the DNA, leadingto the 
carcinogenic process [128].  
The inhibitory and antitumor effects of the green tea polyphenols have been confirmed in more 
than 20 tumor lines. This type of tea, in fact, has been shown to inhibit the carcinogenesis in 
different animal models of prostate, bladder, breast, colorectal, lung, skin, esophagus, and liver 
cancers. Green tea infusion as the sole source of fluid intake in mice, decreased for example the 
induced lung tumor incidence and tumor multiplicity [129-131]. 
Moreover, the inhibition of skin carcinogenesis by tea was investigated: it was found that oral 
administration of green tea reduced induced skin cancer incidence, tumor multiplicity, and tumor 
growth. The inhibitory effect of the polyphenols was associated with reduced expression of 
important factors in tumor growth, metastasis, and angiogenesis. Several in vitro studies also 
demonstrated that tea polyphenols can potently inhibit human breast cancer cells and tumor 
growth [130,131].  
Considering the safety related to the consumption of this drink, the data show that there are no 
real concerns about the consumption of tea by normal people, hence, this does not lead to toxicity 
problems [129-131].  
However, drinking large amounts of tea can cause problems. Tea, in fact, contains caffeine, 
and excessive caffeine intake can lead to nervousness, anxiety, abnormal heart rhythm. High 
caffeine consumption can also hinder calcium absorption, affecting the bone health and increasing 
the risk of osteoporosis. Green tea in elevated doses may also create problems if drunk when a 
person is taking stimulants, hormones, antibiotics or any drug, therefore it is necessary to pay 
attention to those factors [131]. 
Pharmacokinetic studies have shown that there is a correlation between the folic acid and the 
green tea at the level of intestinal absorption: the tea reduces the bioavailability of folic acid, so is 
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not recommended for pregnant women or with megaloblastic anaemia. Furthermore, evidence 
from some case reports suggests that vitamin K content in green tea may antagonize 
the anticoagulant effect of warfarin [132,133].  
In any case, the information on the bioavailability of green tea compounds regarding human 
consumption: more studies on the absorption, distribution and metabolism of polyphenols in 
humans are needed, in order to understand the precise mechanisms of action as agents that can 
help in therapies [132,133]. 
 
 2.5.2 EGCG: (-)-epigallocatechin-3-gallate 
The natural product epigallocatechin-3-gallate (EGCG) is a polyphenolic constituent, precisely 
a catechin, present in high quantities in green tea.  
Many studies have been done on EGCG since it has been suggested as a agent to decrease 
cholesterol levels, repress hepatic glucose production, and enhance insulin action, and to act as an 
antibiotic and anti-carcinogen. This compound has been shown to regulate dozens of disease-
specific molecular targets. The exact mechanism of action of EGCG regarding a number of these 
effects is not entirely clear [134].   
 
2.5.2.1 Structure of EGCG  
EGCG has three aromatic rings (A, B, and D) that are linked together by a pyran ring (C) 
(Figure 16). The health-promoting function of EGCG is attributed to its structure. For example, the 
antioxidant activity of EGCG results from the transfer of a hydrogen atom or single-electron 
transfer reactions, involving hydroxyl groups of the B and/or D rings.  
The pyrogallol-type structure of the B-ring induces apoptosis and possesses strong antioxidative 
activity undergoing autooxidation to form reactive oxygen species. The galloyl moiety (D-ring, 
gallate group) is the critical structure for the inhibition of fatty-acid synthase leading to cytotoxicity 
in human cancer cells. Both components B and D contribute to the exertion of biological activities 
related to the cell-surface receptor [135,136].  
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Figure 16: Chemical structure of epigallocatechin-3-gallate  
(retrieved from [136]).   
2.5.2.2 Antitumor effects of EGCG 
The anticancer property of EGCG is the focal point of researches. EGCG can inhibit 
tumorigenesis by reducing carcinogen activity. There are results suggesting that EGCG prevents 
obesity-related liver tumorigenesis by inhibiting the growth factors and attenuating chronic 
inflammation [138].  
It can also restrain tumor proliferation by acting against angiogenesis (which provides oxygen 
and nutrients to tumor cells), and it also can inhibit pancreatic cancer tumor growth and metastasis. 
Moreover, it is able to inhibit tumor migration and penetration and induce tumor cell death via 
several mechanisms including capase-dependent apoptosis, capase-independent apoptosis, 
lysosomal membrane permeabilization-mediated cell death, and autophagy. It is widely accepted 
that hepatocyte growth factor (HGF) is involved in tumor migration and invasion, and EGCG has 
the capacity to suppress its activity [139-141].   
In fact, most of the anticancer effects of EGCG play a role via several signal transduction 
pathways, but in general the mechanism of anticancer effect of EGCG is multiple and complicated 
[139-141]. 
2.5.2.3 Antioxidant and pro-oxidant effect 
Antioxidation is a process of vital importance to the health of human body. On the basis of the 
chemical structure of EGCG, it results to be an antioxidant. The phenol rings in EGCG structure, in 
model chemical systems, act as electron traps and scavengers of free radicals, inhibit the 
formation of reactive oxygen species, and reduce the harm caused by oxidative stress. It is 
reported that EGCG can effectively inhibit oxidative stress induced by oxidative stress in blood 
platelets, and as an antioxidant it can improve the function of mitochondria. However, under 
typical cell culture conditions, green tea polyphenols are unstable and undergo auto-oxidative 
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reactions: there are some studies pointing out that high concentration of EGCG can cause self-
oxidization and act as pro-oxidant by producing hydroxyl radicals, hydrogen peroxide, and 
quinonoid intermediates causing cytotoxicity. The pro-oxidative effects are apparently responsible 
for the induction of apoptosis in tumor cells, thus being very important for eliminating the growth of 
mutated cells and limiting tumor growth [142-145].  
 
2.5.2.3 Bioavailability of EGCG 
Considering the bioavailability of EGCG, the detailed pharmacokinetics of tea catechins in 
humans and rodents have been studied and the preclinical pharmacokinetic studies reported that 
EGCG has low oral bioavailability (2–13%) in both humans and rodents. There are multiple 
processes which contribute to the low bioavailability of EGCG, including low solubility in the 
gastrointestinal fluid, slow and hard absorption, fast metabolism and elimination system and wide 
tissue distribution.  
Another factor that leads to a low bioavailability is the instability of EGCG in neutral or alkaline 
medium, since the basic medium favors its autooxidation that generates superoxide and hydrogen 
peroxide anions. In this way, many of its effects may be attributed to the production of Reactive 
Oxygen Species (ROS). Due to its low bioavailability, it is unlikely that high EGCG concentrations 
will be reached in the bloodstream of individuals who ingest only two or three cups of 200 mg of 
green tea a day [146].  
Other clinical studies have examined the pharmacokinetic profile of EGCG oral administration 
in healthy subjects. The safety, tolerability, and pharmacokinetic properties of a single dose 
administration of EGCG ranging from 50 mg to 1600 mg were examined. It was demonstrated that 
only for oral doses > 1000 mg of  EGCG, maximal plasma EGCG concentrations > 1 μM were 
observed, considering that the peak concentrations are reached between 1.3-2.2 h after 
consumption with a variation between 130-3.392 ng/mL [146,147].  
It was also evaluated the safety and plasma kinetics of multiple-dose administration of EGCG 
(twice-daily over a four-week period). The results showed that EGCG intake at the doses of 400 
and 800 mg established a peak serum concentration. However, an increase in EGCG 
bioavailability was only observed after chronic 800mg administration and a daily EGCG 
administration produced only minor gastrointestinal side effects [147].  
Rats and mice were also studied and the distribution of EGCG was observed in multiple 
tissues. The highest concentration of EGCG was detected in the large intestine and significant 
concentrations of EGCG were also found in the kidneys, prostate, and lungs [148].  
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It was concluded that the EGCG reaches concentrations within values capable of potently and 
specifically inhibiting some important molecular targets, through the consumption of green tea or 
the dietary supplements rich in EGCG. These studies also suggest that frequent consumption of 
green tea aids in maintaining a high level of EGCG [146-149]. 
After these analyzes, the interest on EGCG was intensified and many studies about colorectal, 
breast, prostate, lung and other cancer cell lines were performed [150].  
For example, studies with MCF-7 cell line have been performed. They showed there were not 
only significant changes in the growth of these cells (proliferation decreased, and cell death 
occurred after EGCG treatment using the necessary physiological levels), but even non-malignant 
epithelial cells were not affected. Based upon these conclusions, other studies were started using 
different cell lines in connection with the drugs used in chemotherapy, in order to try to analyze 
whether the effects of EGCG can be positive [151-153]. 
 
2.5.3 EGCG in cancer treatment 
There are countless publications that analyze the preventive effect of EGCG in some 
neoplasms and, possibly, as a helper in treatment. Due to its molecular focus, different cell lines 
can be influenced both by the inhibition of enzymatic activities, oxidative and anti-oxidative actions, 
and by affinity for specific protein targets [154]. 
This agent has shown considerable anti-cancer effects in a variety of preclinical cell culture 
and animal model systems and, as mentioned before, EGCG can help to induce apoptosis, 
modulation of cellular proliferation and inhibition of angiogenesis and related mechanisms [154]. 
 
2.5.3.1 EGCG in breast cancer  
Chao-You Huang et al. investigated the effects of EGCG on the apoptosis of the human MCF-
7 cancer cell line and the underlying mechanism. MCF-7 cells were divided into control and EGCG 
groups. The proliferation of MCF-7 cells in the two groups was determined using MTT and 
apoptosis was examined using flow cytometry. Western blot analysis was used to analyze p53 (a 
protein that detects the presence of damaged DNA) and Bcl-2 (a protein that regulates cell death) 
expression levels and the silencing effect of specific siRNA. In conclusion, the results showed that 
EGCG suppressed the proliferation of human MCF-7 breast cancer cells and promoted apoptosis 
and the mechanism may be related to the p53/Bcl-2 signaling pathway [151].  
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Liang et al identified that EGCG inhibited the proliferation of breast cancer cells by repressing 
cycling-dependent protein activity and also inhibited the growth and metastasis of breast cancer 
cells by down-regulating the expression of VEGF (vascular endothelial grow factor) and MMP-9 
(an enzyme involved in the degradation of the extracellular matrix) [155,156].  
The effects of EGCG and other catechins on the cell cycle progression were also investigated. 
DNA flow cytometric analysis indicated that 30 µM of EGCG blocked cell cycle progression at G1 
phase in asynchronous MCF-7 cells. EGCG also inhibited the activities of cyclin-dependent kinase 
2 (Cdk2) and 4 (Cdk4) in a dose-dependent manner: as the cells were exposed to EGCG (30 µM) 
over 24 h, a gradual loss of both Cdk2 and Cdk4 kinase activities occurred. These results suggest 
that EGCG may exert its growth-inhibitory effects through modulation of the activities of several 
key G1 regulatory proteins such as Cdk2 and Cdk4 [155,156].  
Another group of investigators, Abd El-Rahman et al., performed an in vivo study in order to 
investigate the effect of EGCG on 3 groups of female rats, injecting them with mammary tumor 
metastasis and evaluating the effect of EGCG on angiogenesis and CSCs. As therapy, EGCG, 
paclitaxel or their combination were used. It was found that EGCG exhibited significant 
chemopreventive effects and anti-CSCs (anti-cancer stem cells) activity through several pathways, 
including a significant decrease in the size and number of tumors in rats. This is a significant 
improvement of the oxidative stress markers’ alterations and a significant inhibition of CD44 (a cell-
surface glycoprotein involved in cell–cell interactions, cell adhesion and migration), VEGF 
(Vascular endothelial growth factor), Ki-67 (a cellular marker for proliferation) and MMP-2 (a 
proteins involved in the breakdown of extracellular matrix) expression associated with a 
significantly increased expression of caspase-3 (a protein playing a central role in the execution-
phase of cell apoptosis). Additionally, the combination of EGCG and paclitaxel significantly 
enhanced the later anticancer efficacy, and it was concluded that EGCG could be offered as a 
curative strategy to help cancer treatment [157]. 
 
2.5.3.2 EGCG in colorectal cancer 
Kumar et al. tried to discuss the use of EGCG as a chemopreventive agent for prevention of 
colon carcinogenesis and present evidence for the efficacy and safety of this agent based on 
epidemiological, animal, in vitro studies and Phase I clinical trials. Epidemiological studies, 
performed in Shanghai using a large population-based case-control diagnosed  cancer cases 
compared to controls, have demonstrated the cancer preventive properties of green tea 
polyphenols in this type of cancer. These findings provide evidence that green tea drinking may 
lower the risk of colorectal cancers [158,159].  
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Considering animal studies, the effects of green tea extract, given as drinking fluid, on the 
promotion/progression phase of colon carcinogenesis in rats, after induction of the neoplastic 
process, was determined. Adult rats were injected with colorectal cancer cells and then were 
randomly divided into two groups: one group received daily prepared aqueous solutions of green 
tea extracts; the control group received water. After six weeks, rats receiving green tea showed a 
60% reduction in the number of colonic pre-neoplastic lesions and a significant decrease of 
cyclooxygenase (COX)-2 activity. Thus, the data demonstrated that green tea reduces COX-2 and 
suppresses the formation of colonic pre-neoplastic lesions [160].  
Ju et al, using another animal model, investigated the effects of green tea and a high-fat diet 
on arachidonic acid metabolism and aberrant crypt foci (ACF) formation in an induced colon 
carcinogenesis mouse model. The female mice were maintained on either a high-fat (20% corn oil) 
or a low-fat (5% corn oil) diet. Two weeks after the injection, green tea was given as the drinking 
fluid and continued for 10 wk until the experiment was terminated. In the mice not receiving green 
tea, the high-fat diet significantly enhanced colonic levels of enzymes, but it did not significantly 
alter prostaglandin E2 levels and aberrant crypt foci formation. In treated mice with the high-fat 
diet, green tea treatment significantly decreased colonic levels of some enzymes and also 
decreased the number of aberrant crypt foci. The weights of fat pads were increased by the high-
fat diet and decreased by green tea treatment. Therefore, this study shows that green tea inhibits 
ACF formation in mice on a high corn oil diet, suggesting its possible inhibitory effect on colon 
carcinogenesis in populations such as those in Western countries that consume high amounts of 
fat [158,161].  
In vitro studies have highlighted that tea compounds reduce growth and/or induce apoptosis in 
several human cancer cell lines. In particular, EGCG has been shown to affect several signal 
transduction pathways in vitro in the colon cancer cell lines. The proteasome system plays an 
important role in the regulation of apoptosis and in the degradation of cellular proteins, and two of 
the proteasome functions are to allow tumor cell cycle progression and to protect tumor cells 
against apoptosis. Following these considerations, EGCG showed the strongest inhibitory activity 
against purified 20S proteasome, 26S proteasome of tumor cell extracts, and 26S proteasome in 
intact tumor cells, being able to help treating cancer [158,162].  
In summary, the in vitro and in vivo studies indicate that EGCG is a promising 
chemopreventive agent, with several cellular effects, both genomic and non-genomic, which are 
critical elements required to effect chemoprevention [158,162]. 
 
 
 47 
 
2.6 Drugs used in chemotherapy – side effects 
In recent years, cancer therapy has evolved a lot and is one of the most important aspects to 
reduce the mortality rate linked to cancer. 
The problem is that chemotherapy drugs travel throughout the body and may have many adverse 
effects. Chemotherapy drugs, in fact, works on active cells: cells that are growing and dividing into 
more cells of the same type. Cancer cells are active, but it is the same for very active healthy cells. 
Hence, chemo drugs can also affect normal and healthy cells that are fast-growing and the 
damages produced to healthy cells causes side effects, like the known fatigue, hair loss, 
headache, easy bruising and bleeding, infection, anemia, nausea and vomiting, appetite changes, 
constipation and diarrhea. The normal cells most likely to be damaged by chemo are blood-forming 
cells of bone marrow, hair follicles, cells in the mouth, digestive tract, and reproductive system, but 
also cells of heart, kidneys, bladder, lungs, and nervous system [163,164].  
Cardiotoxicity and other side effects limit the usefulness of treatments for cancer.  The 
development and implementation of intensive anti-neoplastic treatments have greatly improved the 
prognosis of cancer patients but, despite the benefit of this type of therapy, the safety aspect must 
be taken into account [163-166].  
Hence, all chemotherapy drugs have secondary effects and associated risks, and both are 
different from patient to patient. Consideration must be given to previous treatments, to any other 
medications the patient is taking (unrelated to cancer therapy), to the patient's age and to other 
individual characteristics such as particular health problems and temporary or permanent 
conditions. The oncological treatment is always very individualized and the doctor must consider 
each patient in a different way [167,168]. 
Especially due to the numerous undesirable effects of chemotherapy drugs, researchers have 
begun to look for biological compounds that could help in cancer therapy and, in this regard, 
EGCG is one of the natural compounds studied, both individually and compared to natural and 
carcinogenic cells, and in combination with drugs. In combination with chemotherapeutic agents, 
this natural compound can increase the healing effects and also decrease the toxicity [169].  
The therapeutic modalities available for breast and colon cancer include surgery, radiotherapy 
and chemotherapy, studies have been conducted to try to associate chemotherapy and biological 
therapies [169]. 
In fact, as the effect of EGCG on malignant cells has been demonstrated, its effect has then 
begun to be studied in association with drugs used for different tumor cell lines, including colon and 
breast cancer cells. Despite advances in chemotherapeutic treatments, the acquisition of 
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resistance in the course of treatment causes failure of a successful clinical management. 
Considering this problem, in 2015, a study by C. Hernandez et al.  with the MCF-7 cell line was 
performed: doxorubicin-sensitive and resistant MCF-7 cell lines were either first pre-treated with 
EGCG for 24 hours prior to doxorubicin treatment, or directly treated with doxorubicin. The 
doxorubicin-induced cytotoxicity was measured by the MTT assay and the results indicated a 20% 
increase in cell death of doxorubicin resistant cells that were first pretreated with EGCG, compared 
to cells that were treated with doxorubicin without EGCG pre-treatment. Those results suggest that 
pretreatment with EGCG could potentially enhance sensitivity to doxorubicin-induced cytotoxicity in 
doxorubicin-resistant MCF-7 breast cancer cells [170].  
In this area there are several lines of investigation and it is hoped that they will soon have 
clinical applicability to improve chemotherapy efficacy and reduce the adverse side effects. 
 
2.7 In vitro model 
In vitro models are experimental models used when it is desired to evaluate the molecular, 
biochemical, cellular and histochemical behavior of normal or pathological tissues. 
These studies are performed with microorganisms, cells, or biological molecules outside their 
normal biological context, and they are done in labware such as flasks, test tubes and microplates. 
In vitro studies are conducted using components of an organism that have been isolated from their 
usual biological environment, enabling a detailed analysis. Microorganisms or cells can be studied 
in artificial culture media, and proteins can be examined in solutions. In vitro work simplifies the 
system under study, thus the investigator can focus on a small number of components. However, 
results obtained from in vitro experiments may not fully or accurately predict the effects on a whole 
organism [171]. 
Advances in Cell Biology have allowed an increase in the use of this type of experimental 
model. For example, cell cultures from cutaneous neoplasia have been applied in the study of the 
behavior of these tumors [171]. 
  
2.8 Animal Model 
The development of experimental models became important as they aid in the understanding 
of natural biological phenomena, simulating situations of human disease. In medical science they 
allow the best knowledge of physiology, the etiopathogenesis of diseases, the action of 
medications or the effects of surgical interventions. Animal models can be used in all fields of 
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biological research. In the case of experimental models, it becomes important to conceptualize 
animal disease, to mimic the pathological mechanisms that are similar to those of a human 
disease. This animal model must necessarily allow the evaluation of natural, induced or behavioral 
biological phenomena that can be compared to the human phenomena in question [172].  
Considering that they are "biological reagents", the results of the studies and experimental 
analyzes may be affected by the particular conditions of each of the selected species. Considering 
these aspects, the higher the uniformity of the animals regarding the environmental, genetic and 
experimental variables, the lower the number of animals to be used for the study to be valid [172]. 
Thus, animals used in experimentation can be classified according to sanitary status, 
condition, genotype and as experimental model. For example, considering an experimental model 
there are different types of animal models: induced models (experimental models in which the 
animal is submitted to a procedure capable of provoking a morbidity, in order to perform an 
experimental procedure); negative models (a specific disease does not develop, they include 
animals demonstrating lack of reactivity to a specific stimulus and its main application lies in 
studies on the mechanism of resistance to better understand its physiological bases); orphan 
models (describe the naturally occurring condition in non-human species, but has not yet been 
described in humans); adopted models (orphan models in which a similar disease in humans has 
been identified) [172,173]. 
The use of health, genetic and ethical rules to treat the animals is mandatory: animal 
experimentation, in fact, requires that ethical concerns speak louder than scientific interests. Each 
researcher must have a complete understanding of the animal model being used, and of the 
biology and behavior of that species. Researchers must also be aware of the importance of the 
work being conducted, and consider all the premises that justify each specific project based on a 
solid scientific background. 
 The law reinforces the idea that animal experiments must be based on ethical considerations and 
integrity-based assumptions. It is required that the animals satisfy standardized conditions, are 
maintained in controlled environments to meet the sanitary and genetic quality parameters and the 
number of animals used for the experience/study must be as low as possible [172,173]. 
In in vivo studies it is important to follow the principle of the three R’s (reduction, replacement 
and refinement). Each R stands for a principle for the ethical use of animals in 
experiments: Reduction is the application of methods that allow a reduced number of animals to be 
used in a protocol. This can be achieved by detailed planning of the experiments, guaranteeing 
that results will have statistical significance. The use of animals presenting the same or a similar 
genetic background also ensures a low fluctuation of the data, thereby reducing the number of 
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animals which is needed to be used in a study. Refinement consists in the application of methods 
that avoid animal suffering, such as: the use of anesthesia during a procedure and analgesic 
regimens for pain relief during recovery; the use of non-invasive techniques; housing conditions 
that provide a comfortable and safe environment and training the animal to cooperate with 
procedures. Replacement is the major goal for the use of animals in science. It consists on the 
substitution of animals by other models, such as microorganisms or other invertebrates, cell 
cultures, organs or even cellular fractions. The ideal replacement would be a protocol conducted 
with no use of animals [174,175]. 
The mouse has long been the most widely used animal model for in vivo studies and for 
genetic research, as it has anatomical, physiological, biochemical and genetic characteristics 
similar to human beings. Like humans and many other mammals, mice naturally develop diseases 
that affect these systems, including cancer, atherosclerosis, hypertension, diabetes, osteoporosis 
and glaucoma. In addition, certain diseases that afflict humans but normally do not strike mice, 
such as cystic fibrosis and Alzheimer's, can be induced by manipulating the mouse genome and 
environment. Mice are also easy to manipulate, have a high reproduction rate and relatively 
inexpensive maintenance. Due to their small size, they can be kept in small spaces (cages) in 
appropriate installations,certified and approved by the animal welfare service [176]. 
The most common mice used in cancer research are the Balb/c nude mouse. The nude 
mouse was created in the laboratory between 1979 and 1980 in the National Institute of Health in 
the USA through a series of couplings. It derived from a strain with a genetic mutation that causes 
a deteriorated or absent thymus, resulting in an inhibited immune system due to a greatly reduced 
number of T cells. The phenotype is a lack of body hair, which gives it the "nude" nickname [177].  
Given the characteristics of immunodeficiency of the lineage, it is used for immunological, 
infectious and oncological studies. Immunodeficiency makes these animals very vulnerable and 
this can be a limit for some types of research. Under normal conditions, nude mice have an 
average life time of 9 months, but if kept free from pathogenic agents, infections would occur with 
much less frequency and the life time could even reach two years [177-179]. 
It is important to know the basic principles of the anatomy of these rodents to be able to 
identify organs and collect samples and to perform oral and/or injectable administrations and small 
surgeries. The anatomy of this animal model is simple and can be represented schematically in the 
following figure (Figure 17). 
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Figure 17: Representative diagram of the anatomy of the animal used for in vivo studies (adapted from [180]). 
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Chapter 3 
3.  Materials and Methods 
 
This chapter will report on all the materials and methods used in this work. The used cell lines, 
the cell culture, the tea preparation, the animal studies and the realized experiences will be shown. 
 
3.1 Cell lines 
For the performance of this  work, as mentioned in the previous chapter, two cellular lines 
were used: the cell line WiDr (ATCC® CCL-218™), derived from a human colorectal 
adenocarcinoma, and the cell line MCF-7 (ATCC® HTB-22™), derived from human breast 
adenocarcinoma. Both are adherent epithelial cells and have been acquired by the Institute of 
Biophysics of the Faculty of Medicine of the University of Coimbra (FMUC) to ATCC.   
The MCF7 line retains several characteristics of differentiated mammary epithelium, including the 
ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes. 
The WiDr line is negative for Colon Antigen 3 expression, but positive for keratin by 
immunoperoxidase staining and expresses p53 antigen [181,182]. 
Cell lines were kept in the dry transport ice for the minimum time necessary for the transport 
and were grown for propagation. From the original sample, several aliquots were prepared (in 
culture DMEM medium with 10% of FBS and 10% of DMSO), identified and numbered. They were 
stored a few hours at -80°C (Thermo Scientific, Herafreeze HFUT Series, USA) and then 
transferred to a liquid nitrogen container at -190°C (ThermoNorma, Cryoplus 1, USA). The properly 
identified cryotubes were placed in storage racks, assuring the quality of the cell line stored with 
few passages. During short periods of time, some aliquots were kept at -80°C, in a dedicated 
freezer (Thermo Scientific, Herafreeze HFUT Series, USA), aviding the frequent opening of the liquid 
nitrogen container.  
 
3.2 Cell Culture 
Cell culture must take place in sterile and ventilated flasks, appropriate for adherent cells, kept 
in an incubator at a constant temperature of 37°C, with an atmosphere with 5% of CO2 and 95% of 
humidity. All cell manipulations were performed in a special environment of the cell culture room, 
and inside a laminar flow chamber, in order to maintain the asepsis conditions, essential for the 
propagation and preservation of cells. For this procedure a specific equipment is essential: a 
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vertical laminar flow chamber (Holten Lamin Air, HB2448, USA), an incubator (Binder, Dias de Sousa 
S.A., Portugal), an inverted phase contrast optical microscope (CPOM, Nikon Eclipse, TS100, 
Japan), coupled to a digital photography system, and a centrifuge (Heraeus Multifuge 1L-R, USA) 
(Figures 18,19).  
 
             
 
Figure 18: Images of the referred flow chamber, the CPOM and the centrifuge. 
 
 
                                                                    
 
Figure 19: Images of the referred incubator. 
 
The flow chamber is very important since it allows the work in sterile conditions, limiting 
contamination as much as possible. When an operator uses the flow chamber, he must ensure that 
everything entering the chamber and coming into contact with the cells is sterilized and sprayed 
with ethanol 75%. In fact, ethanol 75% destroys the cell membrane of bacteria by denaturing their 
proteins and dissolving their lipids, helping to maintain the environment sterile and aseptic.  
 
Furthermore, a specific environment is required to allow cell adhesion and proliferation, in 
which the temperature is 37°C and the atmosphere is 95% humidified and contains 5% CO2. This 
environment is guaranteed inside the incubator. Finally, the operator must make sure that all the 
material that came into contact with the cells is discarded and placed in special containers, for 
incineration. 
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   3.2.1 Culture medium 
The culture medium suggested by the cell line supplier is the Eagle's Minimum Essential 
Medium (EMEM) (ATCC® 30-2003™), with  2 mM of L-glutamine and 1% of non-essential amino 
acids (NEAA), fetal bovine serum (FBS) at 10% and 1% of antibiotics of pennicillin/estreptomycin 
(Pen/Strep), renewed two or three times a week. 
However, the cell culture medium used in this study was the Dulbecco's Modified Eagle 
Medium (DMEM) (Gibco® 1x, 11966-025, UK), supplemented with 1% of L-glutamine (Biowest, L-
glutamine 100x, 200mM, XO55O-100, USA), enriched with fetal bovine serum (FBS) (Sigma-
Aldrich®, F7524, USA) at 10% and 1% of antibiotics Pen/Strep (Lonza Pen Strep, Amphotericin, B 
100x, 17-745E, USA). The addition of serum to the culture medium is fundamental for the 
contribution of growth factors, hormones, chelating agents and detoxifying substances that induce 
the survival and proliferation of cultured cells (25 mL FBS in 500 mL DMEM).  
DMEM contains approximately four times more vitamins than EMEN and two times more 
amino acids (as ferric nitrate and sodium pyruvate), and some supplementary amino acids (as 
serine and glycine).  
After being prepared, the medium was sterilized by vacuum filtration in the laminar flow 
chamber. Then a test was carried out during at least 48 h – 72 h to check that there were no 
contaminations. If everything was correct, the culture medium stored in a refrigerator could be 
heated in a water bath thermostatized at 37 ° C (Tissue water bath, GFL, 1002, Germany) and 
supplemented with 5% FBS. 
 
3.2.2 Cell thawing 
Before being used, the cells were kept in a cryotube in the cryopreservation mixture  with 
DMEM medium and 10% dimethylsulfoxide (DMSO) (SigmaAldrich, D2650, USA), either in the 
special freezer at -80°C or in the nitrogen chamber at -190°C.  
The cryotube was transported and quickly defreezed by shacking it inside the thermostatized 
water bath at 37°C, containing a preservative – sodium azide (Sigma-Aldrich, S202, USA) to avoid 
fungi development.  
In the laminar flow chamber, the cryotube volume was passed into a 15 mL Falcon (Sarsted, 
62.554.502, Germany) and 2-3 mL of DMEM culture medium were added to inhibit the action of the 
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cryopreservative agent. The 15 mL tube was centrifuged at 1100 rpm (rotations per minute) for 5 
minutes at 4 ° C (Thermo Scientific, Heraeus Multifuge 1L-R, Germany, certified by Certilab). Then, in 
the flow chamber, the supernatant was discarded, thus removing all the suspension medium. The 
obtained pallet was resuspended in 1 mL of DMEM medium and then the cell suspension passed 
into a 25 cm2 culture flask (Corning, 430693, USA), adding about 15 mL of DMEM culture medium, 
an adequate amount to give the cell suspension enough nutrients to proliferate. Hence, the flask 
was placed in the incubator at 37°C and kept in a humidified and controlled environment. The 
culture medium was withdrawn and changed every 2/3 days, after checking the growth of the cells 
under the CPOM. 
An important thing to consider is that the WiDr cells used require a time of 48 h for proper 
adhesion and proliferation, while the MCF-7 cells take 72 h. When plated every kind of 
manipulation with those cell lines must be performed after those periods of time, respectively. 
 
3.2.3 Cell maintenance 
Every day it was checked if cell proliferation and adhesion were progressing correctly and if it 
was necessary to change the culture medium. The flasks with the cells were observed under the 
CPOM, until they reached approximately 70-80% of confluence. 
Cells were detached from the flat bottom flask by an enzymatic method (TrypLE
TM
 Express, 
Gibco by life tecnologies
TM
, Denmark) and transferred into new flasks or plated into culture plates, as 
necessary. The performed procedure is described in the following sub-section (3.2.4). 
As the culture medium has a pH indicator (phenol red), it varies its color and shows a gradual 
transition from red to yellow as the pH value decreases from 7.4. In fact, when the pH value falls 
down, the color turns from red to yellow, and this means that the culture medium is reacting with 
the metabolic products of the growing and proliferating cells, which acidify it. Hence, the coloring of 
the culture medium serves as a visual indicator of its acidity, characteristic of the progression of the 
cell growth and proliferation. If the medium becomes really yellow, it means it is full of toxic 
products formed by the cells themselves. It is advised to change the medium when it is still orange 
to provide new nutrients to the cells, and allow them to continue to proliferate and grow until they 
have space. MCF-7 are very sensitive to low pH and to the lack of space and died very quickly. A 
daily check-up is mandatory. 
If there was a need to change the culture medium, this procedure was done with an automatic 
pipettor (Gilson, Pipetting Aid 080333, France), coupled to a sterile glass Pasteur pipette (VWR, 
Pasteur Pipettes 612-1702, France), to aspirate all the culture medium present in the culture flask, 
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thus removing the cells in suspension and the medium full of metabolites. Then, another 15 mL of 
new culture medium were placed in the flask, and the flask was put back inside the incubator, after 
having been sprayed with 75% ethanol. The flasks were always checked under the microscope 
also to make sure there were no bacterial contaminations. 
 
3.2.4 Cell detachment 
As they grew, the cells adhered to the flat bottom of the flask and to each other. To maintain a 
good growth environment, it was necessary to ensure that the number of cells within the flask was 
such that growth was possible and did not prevent the normal development of the monolayer, 
considering that the cells respond to contact inhibition. In fact, contact inhibition is a signaling 
pathway activated by the glycocalyx present outside the cell membrane, which emits signals to 
contact with cells of the same type. These signals inhibit mitosis and lead to cell death. 
Cancerous cells typically lose this restrain signaling and thus divide and grow over each other in an 
uncontrolled manner even when in contact with neighbor cells, resulting in the invasion of 
surrounding tissues [183].  
Nevertheless, the cell lines used in this work have special characteristic behaviors. WiDr cells 
can grow in piles, building up stalagmite alike structures. If the “mother” flask is kept for longer 
periods, little black dots become visible on its bottom. They stay glued together and this can 
explain the in vivo behavior of this tumor, which is capsulated, thus circumscribing colon cancer in 
the first stages. On the contrary, MCF-7 cells do not grow in heaps, leading to cell floats, and die 
relatively quick when they do not have enough free space to grow. If these floats drive quickly in 
vivo initiating metastasis, a situation that is common in mammary cancer. 
Cell detachment can be done by mechanical or enzymatic methods. In this work, an enzymatic 
degradation was used, digesting the adhesion proteins using a protease. Proteases are necessary 
to break up the extracellular matrix, and thus obtaining individualized cells, aiming to transfer them 
to a new culture flask or to be plated onto culture plates. The non-specific proteolytic enzyme used 
was a recombinant enzyme present in TrypLE
TM
 Express (Gibco by life tecnologies
TM
, Denmark), 
which is specific for arginine and lysine, hydrolysing polypeptide chains in lysine-arginine radicals 
and forming ester and amide cleavage terminations. The reaction is similar to the one caused by 
trypsin, but without derivatives of animal origin, being more gently with the cells. This reaction 
disrupts the matrix, making impossible to bind the cell surface receptors, linked to the cytoskeleton 
and to the matrix, which forces the cells to reorganize their cytoskeleton. Due to the non-specificity 
of the enzyme, the cells were not left in its presence for much time, in order to avoid cell lysis 
(plasma membrane rupture leading to the destruction of the cell). The use of TrypLE is important 
mainly for MCF7 cells that are very sensitive [184,185]. 
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The process was divided in a series of steps: 
1. the culture medium was removed from the flask as described above; 
2. 4 to 7 mL of TrypLE were added to the flask, depending on its size (25 or 75 cm2); 
3. typically cellular detachment occurred after 3-5 minutes for the MCF-7 cell line and after 6-8 
minutes for the WiDr cell line; 
4. after this period of time, the flasks were observed with the CPOM to check if most of the cells 
were in suspension; 
5. once the cell layer was separated, the effect of TrypLE was neutralized by adding 1-2 mL of 
culture medium. Medium contains fetal bovine serum and since the serum possesses alpha1 anti-
trypsin, this neutralized the action of the enzymatic agent; 
6. the cells were suspended by soft pipetting, transferring the cell suspension into 15 mL sterile 
identified tubes, using a pipettor coupled with a sterile Pasteur pipette; 
7. the tubes were centrifuged at 1.100 rpm, for 5 minutes at 4°C;  
8. inside the flow chamber, the supernatant was discarded from the tube;  
9. the cell pellet was re-suspended in 1 mL of culture medium;  
10. the re-suspended pellet was placed in a new flask with about 15 mL of culture medium, the 
flask was then identified, sprayed with alcohol and placed in the incubator to continue proliferation; 
11. for the experiments to evaluate cell proliferation in presence of several compounds, the 
necessary volume was completed for the appropriate concentration of cells with more culture 
medium. The homogenized cell suspension was then seeded in sterile multi-well plates according 
to the experiment design. 
 
3.2.5 Cell counting 
Both for the cryopreservation process and to start any cell feasibility study, it was necessary to 
know the number of available cells and select the number of cells needed (for example to be 
plated), thus that they do not reach the maximum confluence before the end of the experience or 
not to get a cell number too low in order to have a statistical value. To carry out this operation, the 
detachment process described above was performed, with the only difference that the cell pellet 
was not placed into a new flask but was re-suspended in 1 mL of culture medium. From the cell 
suspension 10 µl were then withdrawn and placed in a sterile 2 mL eppendorf (DeltaLab S.L., 
4092.7N, Spain).  
In order to proceed with the count of the approximate number of cells in the pellet, a vital dye, 
trypan blue (Sigma-Aldrich, T0776, USA) (Annexe III [A]), was used. This compound has the ability 
to cross the fragmented membrane of dead cells and, in this way, to mark the non-viable cells blue. 
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Considering this, 10 µl of trypan blue were added to the suspension previously placed in the 2 mL 
eppendorf, outside the laminar flow chamber. Subsequently, 10 µl of the well homogenized mixture 
were pipetted and placed in a Neubauer chamber (Marienfeld Neubauer improved bright-line, 
0640030, German) under a glass lamella (RS, Cover Glass 100 PCS Thickness 0.13-0.17 mm, 
France) (Figures 20 and 21). 
 
Figure 20: Neubauer chamber. 
 
 
Figure 21: Neubauer chamber scheme and insertion of the suspension into the chamber, under 
the glass lamella (adapted from [186]). 
 
The Neubauer chamber allows cell counting with the CPOM, after inserting the mixture into the 
chamber. This chamber contains a 3 mm2 drawn grid, organized in 9 large squares (3 per line), of 
1 mm2 each. Each of the 4 large squares at the outer corners is divided into 16 squares of 0.25 
mm2 each (Figure 22). The large central square (which can be seen in entirely with the 10x 
objective), is divided into 25 medium squares with double or triple lines. Each of these 25 squares 
are divided again into 16 small squares with single lines, hence each of the smallest squares has 
an area of 1/400 mm2. The glass cover is a squared glass 22 mm of width. 
 
 
 
Figure 22: Neubauer chamber grid (retrieved from [186]). 
In this work, cell concentration was determined using the 4 squares at the corners and 
calculating the average number of cells per quadrant. To carry out the insertion of the mixture 
under the lamella, the suspension must be well homogenized in order to avoid cellular 
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agglomerates. A serpentine trajectory should be followed over the scheme of the 16 squares of 
each quadrant and count the number of cells within each square. The cells over the lines of the 
squares are not considered (Figure 23). 
 
 
 
Figure 23: Cell counting scheme (retrieved from [186]). 
 
Since the volume of each small square is 0.1 mm3, taking into account the defined depth of 0.1 
mm between the chamber and the lamella, the total number of cells in the quadrant allows to 
calculate how many cells are present in 0.0001 mL. This means that the total number per quadrant 
will be multiplied by 104. In this way it was possible to count the approximate number of cells that 
were then used for the in vitro and in vivo studies [186,187].  
If the cells were not needed for further growth or for an experiment, they were frozen. 
Cryopreservation took place in specific cryotubes for this purpose, with a volume of 1.5 mL 
(SARSTED, 72380992, German). Sterile 10% DMSO (dimethylsulfoxide) (Sigma-Aldrich, dimethyl 
sulphoxide, D2650 5x5 mL, USA) was added to the cell suspension in culture medium. DMSO is a 
cryopreserving agent which prevents the water present in the cells to crystallize. In this way, the 
cells can survive to freezing at low temperatures. In fact, as the cell suspension was cooled below 
the freezing point, ice crystals are formed and the concentration of the solutes in the suspension 
increases. Intracellular ice can be minimized if water within the cell is allowed to escape by 
osmosis during the cooling process. However, as the cells lose water, they shrink in size and will 
quickly lose viability if they go beyond a minimum volume. The addition of cryoprotectant agents 
such DMSO allows to mitigate these effects [188].  
The cryopreservation tubes with the cell suspension were correctly identified, marking the cell 
type, the number of cells, the date of cryopreservation and the number of passes. Later they were 
placed in a dedicated freezer, at -80°C. 
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3.3 Use of Green Tea Extract 
The natural compound selected for this study was the (-) - epigallocatechin-3-gallate (EGCG), 
which is one of the most abundant constituents of green tea and is considered the main source for 
various health benefits, already mentioned previously. Studies on the national and international 
market were carried out in order to determine which teas and which extracts were the most 
marketed and consumed, trying to understand which ones held the highest concentration of this 
catechin. 
 
3.3.1 Determination of EGCG concentrations 
To achieve the goal of this work it was necessary to know the concentration for each brand in 
order to identify the extracts that had the highest concentration of EGCG, to verify if the data 
provided by the manufacturers were correct, and to assess whether the concentration was similar 
between all the lots. As it is known, the composition and quality of tea varies according to the 
season, the producing country, the climatic conditions and the processing of the leaves.  
High-pressure liquid chromatography (HPLC) technique was applied to determine the 
concentration of EGCG more accurately, and to make sure that the value indicated by the 
manufacturer was correct some suppliers indicate the precise amount of EGCG in their extracts. 
HPLC is a technique that aims to separate, identify and quantify a sample into its components on 
the basis of its molecular structure and molecular composition [189].  
In a simple way, this technique uses a pump to pass a mixture of solvent + sample to be 
analyzed at high pressure (400 atmospheres), through a column that contains an adsorbent 
material. All the components of the sample interact differently with the adsorbent material, causing 
different flow rates for the different components, in fact the components of the sample move 
through the column at different speeds, which are a function of specific physical interactions with 
the adsorbent. The time at which a specific substance elutes (emerges from the column) is called 
retention time and it is an identifying characteristic of a given sample. This process leads to the 
separation and the identification of the components of the sample as they flow out of the column, 
comparing them with known cone-shaped HPLC profiles for "pure" substances (Figure 24) 
[189,190]. 
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Figure 24: Typical setup of an HPLC system (retrieved from [190]). 
 
The studied extracts of green tea were: in GTE powder (MyProtein, Green Tea Extract powder 
500g, 1705807841, UK) and in the form of a capsule, MGTE (MyProtein, Mega Green Tea ExtractTM, 
90 cap 450 mg, UK) e GTEE (ProHealth, Green Tea EGCG ExtremeTM, 100 veggie capsules, 390 mg 
EGCG cap, PH395, USA, certified by the Laboratory Purity&Potency) (Figure 25). 
 
 
 
Figure 25:  Tea extracts. 
 
Data analysis was done with a dedicated software, and a graphical representation 
(chromatogram) was obtained with several peaks, related to the different components of each 
sample. This technique was performed 3 times for each sample to ensure the reliability of the 
results. 
 
3.3.2 EGCG solutions prepared from the extracts 
The HPLC protocol was used to determine the concentration of EGCG in the selected 
extracts. Capsules from different manufacturers, GTEE and MGTE, and GTE powder were used. 
According to supplier information, each GTEE capsule contained 390 mg of EGCG/capsule, for 
MGTE 180 mg of EGCG/capsule and GTE powder contained approximately 10% of EGCG.  
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To prepare the stock solutions, homemade sterile phosphate buffer saline (PBS) (Annexe III 
[B]) was used. PBS is a saline solution that contains sodium chloride, sodium phosphate and 
potassium phosphate. The buffer helps to keep the pH constant. The salt concentration matches 
that of the human body (isotonic). PBS has many uses especially since it is isotonic and non-toxic 
to cells. It can be used to dilute substances. 
The aliquots of prepared stock solutions were duly identified and then frozen at -20°C, 
protected from light (surrounded by aluminum foil). Starting from these aliquots, previously filtered 
in a sterile environment as mentioned before, the necessary dilutions were prepared, in order to 
obtain the desired compound’s concentrations for the different tests. 
For the in vivo studies a solution was prepared using GTEE capsules. The capsules with 
EGCG extract were cut in half and the powder contained inside them was diluted in water to obtain 
a concentration of 24 mg/mL. This solution is 5 times more concentrated than that required to 
produce a plasma concentration of 0.1 µg/mL in a human [191,192].  
An electronic analytical balance was used to weight the powder of the capsules (Radlag, AS 
220/c/2, Germany). The powder was then placed in an Erlenmeyer Schott flask and the previously 
measured volume of water was added. The solution was well homogenized to obtain a complete 
dissolution of the powder and then it was stored at 4°C, protected from light. 
 
3.4 In vitro studies 
In vitro tests allow to test cell lines in a standardized and reproducible form and to evaluate the 
toxicity of a drug or natural product in a controlled environment. Through various techniques, for 
example the absorbance test, it was possible to evaluate the cytotoxicity of the tested agents. After 
studying the physic-chemical properties of the compounds, the in vitro studies were the first to be 
carried out to try to determine and standardize experimental conditions and try to predict in vivo 
conditions.  
All in vitro tests were carried out in a sterile environment, in standardized conditions and 
following well-defined protocols, in order to have more control over external variables. This 
methodology helps to decrease the number of individuals in in vivo studies, also in accordance 
with the 3R's principle and the time taken for the study. 
For the in vitro studies performed in this work, the WiDr cell line was used. The results of the 
MCF7 cell line were retrieved from a past work: for the present work there were not enough cells 
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for both in vitro and in vivo studies and no chemotherapeutic drugs, thus the choice was only to 
perform in vivo studies based on previous in vitro results. 
 
3.4.1 General aims of in vitro studies 
The in vitro tests had the general goal of testing the possible effect of the most abundant 
polyphenol present in green tea, EGCG, in a combined therapy with the agents used in 
chemotherapy, described in the literature, to treat colorectal cancer, using the WiDr cell line. 
If EGCG enhances the action of chemotherapeutic agents, it would be possible to decrease the 
number of chemotherapy cycles or decrease its dosages, helping to reduce the undesirable side 
effects of drugs, that are extremely negative. 
 
3.4.1.1 In vitro studies - WiDr cell line 
Previous studies carried out with the WiDr cell line, at the Institute of Biophysics of the Faculty 
of Medicine of the University of Coimbra by the team, defined an optimized in vitro culture protocol. 
For these studies, 96 well culture plates, with an area of well 0.32 cm2, were used (Costar, Corning 
Incorporation, 3596, USA).  
The optimal number of cells per well was found to be  2.4 x 103 cells, in a volume of 150 µL 
DMEM per well. Adherence time had also been optimized: it was verified that the optimal time for 
the cells to adhere to the flat bottom plates was 48 h, in order to carry out the experiments 
(incubation at 37°C, 5% CO2 and 95% humidity, as described). In this study, the daily consumption 
of EGCG was simulated, hence applications of the same volume of EGCG-rich solutions with 
predefined concentrations were made every 24 h. The effect of this compound has been tested for 
different replication schemes (1, 2, 3, 6, 9 and 12 applications) and with different EGCG 
concentrations (0.01, 0.1, 0.05, 1, 5 and 10 µg/mL) by previous students. 
It was concluded that, for the WiDr cell line, the most relevant concentrations and applications 
were 0.5 and 5 µg/mL of EGCG for 3 applications. 
In the present work several tests have been carried out for the referred situations, in order to 
increase the reliability of the results, always comparing them with the controls. The controls were 
wells in which no EGCG solution was applied, and which were exactly in the same culture 
conditions for the entire time of the experiment. This allowed to analyze cell viability with and 
without application of the compound, simultaneously. 
 64 
 
In previous studies commercial tea infusions, such as Lipton, Twinning’s and Pingo Doce, 
were also tested, preparing infusions with one, two or three bags at a time, but considering that 
teas also contain caffeine, it might not be convenient to all patients. Due to the large volume that 
would have to be drunk, patients with heart and/or kidney problems could be ruled out of the study. 
In this context, powdered or capsule EGCG enriched extracts were selected. 
In the pursue of the proposed goal and to study the possibility of achieving a reduction of the 
chemotherapeutical doses or to reduce the number of therapeutic cycles, the effect of the different 
extracts together with some of these drugs was analyzed. 
In this work it was analyzed if there can be a beneficial synergistic effect between EGCG 
infusions and chemotherapeutic agents. For this purpose cells were plated for incubation with each 
drug (clinical dosages were selected according to the literature and previous studies [193]), with 
tea extracts alone (0.5 and 5 µg/mL of EGCG), and a combination of drugs and extracts for the 
same concentrations, or no compound other than DMEM (controls). Several independent tests 
were performed for each condition in a series of wells per experiment, in order to increase the 
reliability of the results and their statistical value.  
All the tested drugs were obtained through a protocol between the University Hospital of 
Coimbra, and the Institute of Biophysics (FMUC-ICBR/CIBB). These drugs are approved by the 
FDA (Food and Drug Administration) and the EMA (European Medication Agency), and used in 
chemotherapy for colorectal cancer treatment. 
An illustrative diagram of a 96 well culture plate is presented here: each column corresponding 
to a single dosage, in order to increase the statistical value of the results (Figure 26). 
 
 
Figure 26: Illustrative diagram of a 96 well culture plate, containing the seeded cells and culture medium (in 
each well) and the other substances according to the selected distribution. These plates are used   
for the MTT tests to study the cytotoxicity of extracts, drugs and the combination of both. 
3.4.1.2 In vitro studies – MCF7 cell line 
Previous studies carried out with the WiDr cell line at the Institute of Biophysics of the Faculty 
of Medicine of the University of Coimbra by the team, defined an optimized in vitro culture protocol. 
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In these studies, 48 well culture plates with an area of well 1.1 cm2 were used (Costar, Corning 
Incorporation, 3596, USA).  
The optimal number of cells per well was found to be 7.2 x 103 cells, in a volume of 800 µL 
DMEM per well. Adherence time had also been optimized: it was ascertained that the best time for 
the cells to adhere to the flat bottom plates was 72 h, in order to carry out the experiments  
(incubation at 37°C, 5% CO2 and 95% humidity, as described). In this study, the daily consumption 
of EGCG was simulated (chronic consumption was preferable if compared to acute consumption), 
hence applications of the same volume of EGCG-rich solution with predefined concentrations were 
made every 24 h. The effect of this compound has been tested for different replication schemes (2, 
3, 4, 6 and 8 applications) and with different EGCG concentrations (0.5, 1, 5 and 10 µg/mL) by 
previous students, using GTE extract. 
It was concluded that, for the MCF-7 cell line, the most relevant concentrations and 
applications were 0.5 and 5 µg/mL of EGCG for 6 applications. 
Several tests have been carried out for these situations, comparing them with the controls 
(wells remaining in the same culture conditions for the entire time of the experiment), allowing to 
analyze cell viability with and without application of the compound, simultaneously. 
In previous studies commercial tea infusions, such as Lipton, were also tested, preparing 
infusions with one, two or three bags at a time. Nevertheless considering that teas also contain 
caffeine, it might not be convenient for all patients. Due to the large volume that would have to be 
drunk, patients with heart and/or kidney problems could be ruled out of the study. In this context, a 
powdered EGCG enriched extract (GTE) was selected.  
In the pursue of the proposed goal and to study the possibility of achieving a reduction of the 
chemotherapeutical doses or to reduce the number of therapeutic cycles, the effect of the GTE 
together with some of these drugs was analyzed. 
For this purpose cells were plated for incubation with each drug (with the clinical dosages 
selected according to the literature and with previous studies [193,194]), with GTE tea extract alone 
(0.5 and 5 µg/mL of EGCG), and a combination of drugs and extracts for the same concentrations, 
or no compound other than DMEM (controls).  
An illustrative diagram of a 48 well culture plate is presented here: each column corresponds 
to a single dosage, in order to increase the statistical value of the results (Figure 27). 
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Figure 27: Illustrative diagram of a 48 well culture plate, containing the seeded cells and culture medium (in 
each well) and the other substances according to the selected distribution. These plates are used   
for the MTT tests to study the cytotoxicity of extracts, drugs and the combination of both. 
 
3.4.2 Cell viability 
After carrying out the studies previously described, with the seeded cells and stimuli 
application protocols, it was necessary to know how many cells died, and to quantify the cell 
viability. Measurement of cell viability and proliferation are the basis for numerous in vitro assays of 
a cell population’s response to external factors.  The MTT assay was used for this purpose. 
 
3.4.2.1 MTT assay 
The MTT Cell Proliferation Assay measures the cell proliferation rate and, conversely, when 
metabolic events lead to apoptosis or necrosis, the reduction in cell viability. This is a colorimetric 
assay using the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 
The MTT is a yellow salt, due to the presence of a tetrazolyl ring. Viable cells contain NAD(P)H-
dependent oxidoreductase enzymes which reduce the MTT reagent to formazan, by the 
dehydrogenases occurring in the mitochondria of living cells. Formazan is an insoluble crystalline 
product with a purple color. The concentration of these crystals is proportional to the number of 
living cells. The reduction of MTT depends on the cellular metabolic activity: cells with a low 
metabolism hardly reduce MTT, while rapidly dividing cells exhibit high rates of MTT reduction 
(Figure 28) [195,196]. 
 
 67 
 
 
 
Figure 28: Illustrative scheme for the reduction of MTT molecule in formazan by living cells (retrieved from 
[197]). 
The protocol to make the MTT test envisaged that, in aseptic conditions, the medium is totally 
withdrawn from each well and discarded. Subsequently, taking into account the volume used per 
well, new culture medium and 10% of MTT (Sigma, M2128, USA) were added. In this case, after 
removing the 150 mL (or 800 mL) present in the well, 135 mL (or 720 mL) of DMEM culture 
medium and 15 mL (or 80 mL) of MTT were used.  
After this procedure, the culture plate was placed back in the incubator under the same 
conditions for 4 h and was then observed under the microscope. After this time, over the bench, 
the solution contained in each well was discarded and replaced by acidified isopropanol [a solution 
of HCl (VWR, 20255.420, EC) 0.04 N in isopropanol (Honeywell/Riedel-de Hean, 33539, Germany)] 
(Annexe III [C]), in a total volume of 150 mL. This last procedure, consisting in putting isopropanol 
in the plates, does not need to be performed inside the flow chamber, as the membrane of vital 
cells is destroyed by the action of the acidic isopropanol. The plate was then read to be quantified. 
With a good homogenization, which occurred after about 15 minutes, the amount of formazan 
crystals, directly proportional to the number of viable cells, could be read by spectrophotometry 
(ELISA reader BioTek, Synergy HT, USA), coupled to a computer with the Gen5TM Biotek program 
(Bioteck Inc, USA). This optical method is colorimetric and allowed to quantify cell viability by 
reading at two wavelengths (570 and 620 nm). 
 
3.5 In vivo studies 
In vivo studies using an experimental animal model were carried out once the results of in vitro 
studies were favorable, in order to use the fewest animals possible. In this in vivo study the effect 
of GTEE in capsules was tested, after injecting tumor cell lines WiDr and MCF-7 into animal 
models. 
The most widely used animal models in xenotransplantation experiences are nude mice 
(Foxn1) and mice with severe combined immunodeficiency (SCID), which possess mutations that 
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affect the immune system. The nude mice (Foxn1, Balb/c lineage) present an autosomal natural 
recessive mutation on chromosome 11, which causes a lack of hair growth and other alterations, 
such as disturbances in the formation of the thymus gland (in fact these mice are also called 
athymic nude mice) and consequently  their immune system is inhibited and they are deficient in T 
cells. SCID mice have a spontaneous mutation that results to impair the recombination of antigen 
receptor genes leading to the arrest in the development of functional T and B cells [178,198]. 
Immunodeficient animals have also been developed from other species, such as, for example, 
the ATN rats (Rowett Nude Rats), a mutation of Rattus norvegicus [199]. 
The effect of the GTEE in capsules has already been studied in another experimental model: 
male RNU rat [216]. Some preliminary tests were done in nude mice in previous experiments for 
the WiDr cell line trying to establish a reliable tumor development protocol [200]. Hence, an 
aqueous solution of GTEE in capsules was given to the animals as a substituent of water, 
mimicking the protocol for rats. However, the nude mice do not like, and consequently do not drink, 
this beverage. In this in vivo study the effect of GTEE in capsules was tested, after injecting the 
WiDr tumor cell line in nude mice, using an alternative administration via called oral gavage. 
Liquid compounds, in fact, may be administered directly into the stomach of mice and rats via 
oral gavage technique. In this procedure, a flexible cannula (abbocath for gavage feeding) (BD 
Insyte™ Autoguard™ Blood Control, 381034, 20G x 1.16 pol., 1.1 mm x 30 mm) is attached to a 
syringe and used to deliver the compound into the stomach. The correct cannula length is equal to 
the distance from the mouth to just beyond the last rib. The animal was gently restrained (grasping 
the animal by the loose skin of the neck and back) to immobilize the head but not such that the 
animal showed signs of distress. The animal was maintained in an upright (vertical) position and 
the gavage needle was passed along the side of the mouth. Following the roof of the mouth, the 
needle was advanced into the esophagus and toward the stomach. If resistance was encountered, 
needle position was altered, not entering the trachea. After the needle was passed to the correct 
length, the compound could be injected. 
iCBR-FMUC/CIBB has a certified maintenance vivarium and has the authorization for breading 
some rat and mouse lineages, by a specialized staff. The animals were bread and maintained in a 
controlled environment (system of dedicated racks at 24°C, purified air, relative humidity of the air 
maintained between 40-60%, controlled light cycles and noise reduction). The animals were kept in 
disinfected cages (washed and dried with dedicated equipment, using non-foaming detergents and 
disinfectants) with a bed of sterilized corn cob, sterilized playful material and sterilized food. 
The cages, all identified with a label containing indications regarding the lineage, the genus of 
the mice, the number of mice/cage and the date of birth, were placed in the racks connected to a 
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system of filtration of incoming and outgoing air in the referred certified installations. The solid food 
pellets, with the proper nutrients, was sterilized and the water acidified (pH 3-4) and made 
available  through disinfected bottles with metal heads.  
The tumor cells to be injected were cultured in vitro following the previously described culture 
protocol, as well as the following steps for the enzymatic detachment, centrifugation and vital 
staining with blue trypan for counting in the Neubauer chamber. 
A non-orthotopic xenograft model was used and the cells were injected subcutaneously into 
the animal's right thigh.  
The cells, after being detached and centrifuged, were aspirated with a 19G needle, 1,1x25 mm 
(T Terumo Neolus, NN-1925R, Belgium) coupled to a 1 mL syringe (T Terumo Syringe, U-100 
insulin, SS + 01H1, Belgium), duly identified and in ice, in order to prevent cell degradation.  
The subcutaneous injection into the mice was carried out with the same syringe, coupled with 
a 25G needle (BD Microlance
TM
, 25G
5/8’’
, 0.5x16 mm, 300 600, Spain). This inoculation process took 
place inside a laminar flow chamber used for animal handling (Heraeus Holten, HBB 2448, USA) 
previously sterilized with ultraviolet light and cleaned with Virkon (Virkon S, 5 kg, A01576789, UK) 
and alcohol 75 % in accordance with the law in force [Law Decree No. 113/2013, of 7 August - 
national legislation transposing the European Directive 63/2010 / EC and duly authorized by the 
General Directorate of Veterinary Medicine and in agreement with the Agency for Animal Welfare 
(Órgão Responsável pelo Bem-Estar Animal - ORBEA - 17/2015)] (Annexes I and II). 
For the subcutaneous injection, the animal was placed supine and the injection was made with 
extreme care so as not to reach the muscle fascia, not causing unnecessary pain to the animal and 
attaining a blood vessel. After the injection, the animal was put back in its cage.  
The animals were monitored weekly to determine their weight (duly recorded in a notebook), 
using an animal scale (Seca, model 734, series 1/1, Germany), and to check if there were any 
alterations in the area of inoculation or somewhere else (conjunctivitis, wounds, etc.). As soon as a 
tumor mass was detected visually and by palpation, a photographic recording was made and the 
mass was measured (width and height) with a caliper (Wurth, stainless hardened, Germany). These 
measurements were performed weekly in the same controlled environment and by the same 
investigators. 
3.5.1 WiDr cell line 
In this study, Balb/c nude mice, about one month and a half old, were used. Male mice were 
injected with 3-4x106 WiDr cells, resuspended in 0.2 mL of culture medium. For this study, 15 
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Balb/c nude mice were used. The animals started taking EGCG enriched solutions when the tumor 
reached the size of 1 mm2.  
The animals were divided into two groups: 
- group 1: animals injected with WiDr tumor cells, drinking water (control), 
- group 2: animals injected with WiDr tumor cells, drinking water + GTEE extract by gavage once a 
day. 
The occision of the animals was programmed when the tumor reached the maximum 
regulated proportions and performed by anesthesia overdose, having met all the requirements of 
the legislation in force [201]. 
 
3.5.2 MCF-7 cell line 
Following the in vitro studies previously performed by other students [178], female nude mice 
were injected with MCF-7 cells (cultured, detached counted and resuspended according to a 
similar protocol as for the WiDr cells). The significant alteration is the 5-6x106 MCF-7 cells were 
injected sc. The MCF-7 cell line forms tumors in animal models only in the presence of estrogen. 
This administration/dosage procedure was carried out in accordance with the information gathered 
in the bibliographic review [202,203]. Thus, one week after the subcutaneous inoculation of MCF-7 
tumor cells, a suspension of 2 mg of estradiol (Sigma, E8750, USA) was prepared, in 1 mL of 
sesame oil (Sigma, S3547, USA), previously filtered with 0.2 µm filters to an eppendorf in sterile 
conditions (inside the laminar flow chamber used to prepare cell suspensions). After vortexing to 
reach homogenization (Unimag ZX3 Vortex Mixer, D-82152, Germany), 0.3 mL of the solution were 
withdrawn with a 1 mL syringe coupled to a 19G needle. The s.c. administration was done with a 
25G syringe, just like cell inoculation, but in the right upper quadrant of the dorsum of the animal.  
The animals were controlled in the exact same way as for the WiDr protocol. Animals were 
divided in two groups: 
- group 3: animals injected with MCF-7 tumor cells, drinking water (control), 
- group 4: animals injected with MCF-7 tumor cells, drinking water + GTEE extract by gavage 
once a day. 
 
3.6 Positron Emission Tomography – easyPET-3D 
Positron emission tomography (PET) is a nuclear medicine imaging technique, used for clinical 
diagnostics, for example in early stage cancer detection, but also in preclinical studies, in order to 
develop and test new diagnostic and therapeutic agents, prior to clinical trials. It allows to obtain 
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information on the functional stage of the organs, detecting the positrons emitted by the 
radionuclide used [204].  
The PET technique is based upon the detection of the radioactivity emitted by the organs, after 
the injection of a small amount of a radioactive tracer into the subject to be analyzed. A 
radiopharmaceutical is a substance composed by a radioactive atom linked to a chemical 
substance. The radiopharmaceutical will be taken up by the tissue/organ during its metabolic 
processes. The nucleus of the radioactive atom emits a positron, which collides with an electron in 
the tissue and in this process mass is converted into energy, in the form of two photons, with an 
energy of 511 keV each. The conventional PET system uses scintillation crystals positioned 
around the subject to detect the photons: crystals absorb photons and produce light which is then 
converted into an electrical signal (Figure 29) [204-206]. 
 
 
 
Figure 29: Scheme of the process that allows the generation of images (adapted from [204]). 
The generated photons have opposite directions and they are detected by collinearly aligned 
detectors pairs, in coincidence. The pairs of detectors of a PET conventional system are built-in in 
a ring-like pattern. Only coincident events between the rings are acquired and generate valid data. 
Hence, the obtained image is given by the location of the positron emission from the 
radionuclide absorbed by the subject's organs. Thanks to a suitable software based on specific 
reconstruction algorithms, it is possible to reconstruct an image of the emitting zones, starting from 
the energies and the directions of each pair of gamma rays, with the help of a computer, 
generating three-dimensional images [204-206]. 
By identifying body changes at the cellular level, PET may detect the early onset of disease 
before it is evident on other imaging tests, showing the function, but not anatomical details. For this 
purpose, hybrid systems were developed: PET + CT or PET + MRI. 
Preclinical micro-PET systems play a key role in the evaluation of new drugs and therapies, as 
well as in the study of the biological origin of several human diseases through the imaging of 
 72 
 
appropriate animal models. However, a pre-clinical micro-PET system costs between € 0.6 and € 
1.2 M, limiting the access to research centers in the fields of nuclear medicine, medical imaging or 
radiopharmacy. This situation makes PET systems of this kind completely inaccessible to be 
purchased by universities or health schools.  
The equipment used in this project is called easyPET-3D and it was developed by a 
collaborator team of the University of Aveiro (CENTRO-01-0247-FEDER-017823, SII & DT 17823; 
PTDC/bbb-img/4909/2014) (Figure 30). 
 
 
Figure 30: The easyPET-3D system. 
 
The easyPET-3D technology is a new concept of PET, based upon an innovative PET image 
acquisition method, using only 2 sets of detectors that rotate intelligently according two axes, 
covering the same field of view of conventional PET systems - which use a complete detector ring, 
performing a full 2D image similar to the one obtained with a ring scanner (Figure 31).  
 
 
Figure 31: EasyPET-3D working principle scheme (retrieved from [207]). 
In each position the scanner acquires a fanbeam projection: a fan rotation is used to cover the 
entire field of view (FoV). When a coincidence is detected between the two scintillation detectors, 
the line-of-response (LOR) is the line between the two front faces of the scintillation detectors. 
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The innovative method of image acquisition dramatically reduces the complexity and costs of 
production, allowing democratization of access and use of PET technology. The developed system 
has a completely innovative architecture, with a reduced number of components and, therefore, it 
is much simpler and economical. Simultaneously it has a high performance, particularly in terms of 
spatial resolution and uniformity, due to the intrinsic capacity of the method to eliminate uncertainty 
in the position associated with depth of interaction (DOI). The easyPET-3D, with a single pair of 
collinear crystals, can not detect the obliquely incident photons nor the photons undergoing 
Compton scattering in neighboring crystals. As a result, a good imaging capability without 
aberration effects and a high spatial resolution are expected. In addition, the original 
implementation of the acquisition method based upon two degrees of freedom ensures a uniform 
spatial resolution over all the FoV without the need to measure the DOI. One potential fragility of 
this concept is the reduced geometrical acceptance due to the use of only two detectors, which 
limits the slice sensitivity of the system. The basic idea is to exploit the absence of effects 
degrading the image quality to partially recover the events lost because of the system geometry 
[207-210].  
The projected solution will enable the use of this PET system in pre-clinical environments, 
since due to its lower cost it will become accessible to a much wider range of institutions. The 
easyPET-3D allows an improvement of the educational offer for universities and health schools, by 
opening the possibility of teaching/learning how to perform the PET imaging. Pre-clinical tests 
using radioactive biomarkers in small animals (in vivo), in a controlled environment for image 
acquisition, can then be applied in very different areas of medicine using the easyPET-3D system 
developed by the team, especially in oncology and neuroimaging studies. 
The radionuclide used in this work was the fluorodeoxyglucose (FDG), labelled with Fluoro-18 
(18F), a glucose analogue, which allows studying the metabolism of organs and tissues. The 18F 
has a half-life of about 2 hours (109.8 min). Glucose is a simple sugar and it is used by the cells as 
the main source of energy. Considering that tumor cells have an altered metabolism and use an 
enormous amount of glucose to support their rapid expansion and proliferation, the FDG, being a 
glucose analogue, is accumulated in the tumor site, allowing its detection and visualization thanks 
to the PET system [211-213]. 
For the acquisition of the images a specific protocol was optimized by the team. The activity 
was measured and injected into the animal, and an hour (time required for the uptake of the 
radionuclide), the animal was anesthetized with a mixture of ketamine (Cetamine Hikama 50 mg/mL, 
Hikma PharmaceuticalsTM, Portugal) and chlorpromazine (Largactil, 5 mg/mL, Laboratórios Vitória, 
Portugal) in a proportion of 1:3. Ketamine is a medicine used primarily to induce and maintain 
anesthesia, acting as an inhibitor of NMDA activity (the main receptor responsible for measuring 
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the excitatory response of the central nervous system), which in turn is responsible for the increase 
in glutamate activity (one of the main neurotransmitters in the human body). Chlorpromazine, on 
the other hand, acts as a relaxant and tranquilizer without causing sedation, blocking the impulses 
generated by dopamine in the synapses. 
For mice, 0.1-0.3 mL of anesthetic mixture diluted in equal parts (1:1) with saline were 
administered intraperitoneally (i.p.). After anesthesia, the animals were placed on the bed of the 
equipment to perform the study and were kept at a constant temperature of about 37°C, thanks to 
a water heating pump (Adroit Medical System, HTP-1500, USA) coupled to the easyPET-3D 
equipment. This pump allowed to maintain constant the temperature of the anesthetized animal 
that, otherwise, would suffer a body temperature lowering. The used animals are nude, hence the 
increased probability to body cooling which would implicate muscle contraction and shivering, 
situations that must be avoided for a good imaging acquisition. 
The 18F-FDG (ICNAS, IBA Cyclone, Portugal) was administered to the animals via 
intra-peritoneal (i.p.). Following this procedure, it was internalized by the cells through the usual 
glucose transporter, and it was not metabolized inside the cells, but converted into a form which 
was kept inside. Therefore, 18F-FDG can be used to detect cells with high glucose consumption 
and consequently contain a large number of membrane transporters, as happens in fast-growing 
tumor cells, allowing the display of the tumor mass induced in the animals. 
The radioactivity was transported from the hospital to iCBR using a protected lead case and all 
manipulations of the radioactivity took place in a special chamber, behind a lead protected shield. 
The 18F-FDG dose to be injected in nude mice, for a single acquisition, was between 220 and 400 
µCi and it was measured with a dose calibrator (CRC-15 W, Capintec, USA) in a 1 mL syringe (T 
Terumo™ Syringe, U-100 insulin, SS + 01H1, Belgium) coupled with a 25G needle (BD Microlance™, 
25G, 5x8 ''; 0.5x16 mm, 300600, Ireland), in accordance with the safety regulations for handling 
radioactive substances (Protector Shield Biodex, USA). 
Not only the tumor, but also other organs, such as the bladder (which is an excretory organ), 
the heart and the brain are clearly identified with a PET system. Areas with inflammation also show 
a high glucose activity due to the increase in metabolism of the injured areas. 
  
3.7 Histological tests 
The histological technique consists of a set of steps to prepare a tissue for microscopic 
analysis, either for scientific research or pathological diagnosis. Procedures include material 
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collection, fixation, processing, inclusion, microtomy, and staining. In the case of calcified tissues, 
after fixation it is necessary to decalcify the tissue. 
The collected samples were placed in cassettes (PrintMate ™ Embedding Cassette, 
A84810048) and, immediately afterwards, the procedure began, avoiding tissue degradation due to 
the action of the enzymes present in the cells. The first step was fixation: the cassettes were 
placed into a container with 10% buffered neutral formalin fixative which penetrates the tissue 
replacing all tissue water, thus preserving the sample. 
After fixation, the sample was processed in order to impregnate the tissue in a solid and firm 
medium, allowing to obtain thin sections that could be stained and viewed under the optical 
microscope. The processing consisted of several steps. The first step was tissue dehydration: 
ethanol solutions of increasing concentration replaced water and fixative in the tissue. After this 
step, tissue was diaphanized: material was clarified, making it translucent, by removing ethanol 
and replacing it with a miscible fluid with an impregnation medium, the most commonly used 
xylene. In the impregnation process, the diaphanizing agent was replaced by the impregnating 
medium. At this stage, the samples were infiltrated by a substance with firm consistency (liquid 
paraffin), in order to acquire sufficient rigidity. At the end of the impregnation, a block containing 
the tissue was obtained, and was cut using microtome. 
The cut material was then placed on the glass slide for drying and adhesion, and goes through 
processes that allowed to seal the cut. 
The cuts coloring allowed to highlight the tissue components or to distinguish between 
different tissue structures. The staining process was hematoxylin-eosin, which is a simple 
technique allowing the differentiation of a large number of tissue structures. Hematoxylin is a basic 
dye that stains in dark blue/purple color the acidic components of the cell (such as DNA and RNA), 
staining the nucleus and ribosome-rich cytoplasm regions, while eosin is an acid dye that stains in 
pink color the basic components of the cell (such as cytoplasm and connective tissue fibers). To 
allow staining process, since the dyes are watery, deparaffinization and hydration of the cuts were 
performed. 
After staining, the slides were dehydrated again and the procedure was repeated until the 
diaphanous agent. In order to protect the cut samples, the glass slides were covered with a 
coverslip glued with synthetic glue which, after drying, could be analyzed by an optical microscope. 
As it was coupled to a computerized system with an adequate software, the processing and 
recording of the obtained images in digital media was performed. 
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3.8 Statistic analysis 
In order to compare between groups/conditions, the non-parametric Kruskal-Wallis test was 
used, due to the lack of Gaussian distributions. In Statistics, the Kruskal-Wallis test is a 
non-parametric test that does not assume that the populations follow Gaussian distributions, but it 
assumes that the shapes of the distributions are identical. It compares three or more unpaired or 
unmatched groups, aiming to verify if these groups come from the same population (or from 
populations with equal median). If the p value is low, the population medians are different. The null 
hypothesis says that “the distribution of MTT is the same across categories of substances”.  
The aim of this test is to evaluate the differences in the values resulting from MTT. In order to 
assess the efficacy on cell viability of the different green tea extracts, adequate comparisons were 
performed with the respective controls of these tests. All p values were obtained using SPSS® 
Statistics, version 23 (IBM Corporation, Armonk, USA), and GraphPad Prism software, version 5, for 
the analysis of cytotoxicity data, analyzing the results with a significance level of 5%. 
Results are presented using diagrams of extreme and quartile. 
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Chapter 4 
4. Results and Discussion 
 
This chapter presents and describes the results obtained using the methods described above 
and their discussion. 
 
4.1 In vitro studies 
4.1.1 MTT test 
Several cell viability studies were performed to test the cytotoxicity of EGCG-enriched 
solutions for the WiDr tumor cell line, of the drugs used in colorectal cancer therapy (isolated and 
in some combination regimens) and of EGCG solutions co-administered with some of these drugs 
in the same therapeutic regimens. The specificity of EGCG for tumor cells has been confirmed in a 
previous study comparing to the normal cell line of CCD colon CCD 841 CoN [216]. Below there 
are the diagrams of the extremes and quartiles obtained for the MTT tests (tests carried out with 3 
applications of EGCG every 24 h and a single pharmacological application on the first day; all 
carried out in 96-well plates with 2.4x103 cells/well and DMEM to reach a volume of 150 µL). 
 
4.1.2 WiDr cell line 
4.1.2.1 Tea extracts 
The green tea extracts enriched with EGCG used in the following in vitro experiments were: 
Green Tea EGCG Extreme (GTEE) capsules, and Mega Green Tea Extract (MGTE) and Green 
Tea Extract powder. The concentrations used for all 3 extracts were 0.5 µg/mL and 5 µg/mL. 
Those concentrations were selected in conclusion to another study in which 0.01, 0.1, 0.5, 1, 5, 10 
µg/ml concentrations were tested [193].  
The first tests were carried out considering these tea extracts. The graphs below, on the left 
(Figure 32A), show the percentage of cell viability in the presence of the extract compared with the 
control (which is considered with 100% viability) and on the right (Figure 32B) the comparison of 
the MTT values for the different extracts to the control. Considering the results provided by the 
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Kruskal-Wallis statistical test, the MGTE and GTE extracts show statistical significance comparing 
with control: the cell viability with the tea extracts is significantly lower than the one for the control, 
corresponding to the tumor cells only with culture medium (no other compounds). The GTEE 
extract, on the other hand, does not show statistical significance according to the Kruskal-Wallis 
test: the cell viability, in this case, is not much lower than the control. Everything can be observed 
in the following figure (Figure 32). 
[A]  [B] 
Figure 32: Graphs highlighting the percentage of cell viability [A] and the extremes and quartiles diagram [B] 
for MTT tests: controls and tea extracts (GTEE, MGTE, GTE) with 0,5 μg/mL and 5 μg/mL 
concentrations. 
 
4.1.2.2 Capecitabine (CAP) (control vs drug vs drug+EGCG) 
CAP monotherapy at a dosage of 350 ng/well does not induce a very marked decrease in cell 
viability compared to controls. However, when the drug was combined with an EGCG 
concentration [GTEE ([EGCG] = 0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 μg/mL), GTE 
([EGCG] = 0.5 and 5 μg/mL)] a marked decline in cell viability, compared with controls and also to 
monotherapy, can be seen. The differences turned out to be statistically significant especially for 
GTEE 0.5 μg/mL and for GTE 5 μg/mL (Figure 34). 
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Figure 33: Extremes and quartiles diagrams for MTT tests: controls, CAP, CAP + GTEE 0.5 and 5 μg/mL, 
CAP + MGTE 0.5 and 5 μg/mL, CAP + GTE 0,5 and 5 μg/mL. 
 
4.1.2.3 5-Fluoracil (5-FU) (control vs drug vs drug+EGCG) 
Monotherapy performed with 5-FU at a dose of 112 ng/well induced a non-statistically 
significant reduction in cell viability compared with the control. The reduction, according to the 
Kruskal-Wallis test, became statistically significant when the tea extract were added GTEE 
([EGCG] = 0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 μg/mL), GTE ([EGCG] = 0.5 and 5 
μg/mL) compared with the control (Figure 34A). Furthermore, there was a statistically significant 
difference for the drug combined with GTEE ([EGCG] = 0.5 μg/mL) and GTE ([EGCG] = 0.5 and 5 
μg/mL), compared to the monotherapy with this drug (Figure 34B). In the other cases the reduction 
of cell viability was not statistically significant if compared to the monotherapy drug. 
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 [A]  [B] 
Figure 34: Extremes and quartiles diagrams for MTT tests: controls, 5-FU, 5-FU + GTEE 0.5 and 5 μg/mL, 
5-FU + MGTE 0.5 and 5 μg/mL, 5-FU + GTE 0.5 and 5 μg/mL [A];  5-FU + GTEE 0.5 μg/mL, 5-
FU +   GTE 0.5 and 5 μg/mL [B]. 
4.1.2.4 Irinotecan (IRI) (control vs drug vs drug+EGCG) 
Monotherapy performed with IRI at a dosage of 98 ng/well induced a decrease in cell viability 
compared to controls. When GTEE ([EGCG] = 0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 
μg/mL) or GTE ([EGCG] = 0.5 and 5 μg/mL) were added to the treatment, cell viability also 
decreased significantly in both cases compared to the control and to the drug alone. The Kruskal-
Wallis test, in fact, showed a statistically significant difference in cell viability between control, 
monotherapy and combined monotherapy (Figure 35A) and between monotherapy and combined 
monotherapy (Figure 35B), without a particular preference among the brand of the extract. 
[A] [B] 
Figure 35: Extremes and quartiles diagrams for MTT tests: controls, IRI, IRI + GTEE 0.5 and 5 μg/mL, IRI + 
MGTE 0.5 and 5 μg/mL, IRI + GTE 0.5 and 5 μg/mL [A];  IRI, IRI + GTEE 0.5 and 5 μg/mL, IRI + 
MGTE 0.5 and 5 μg/mL, IRI + GTE 0.5 and 5 μg/mL [B]. 
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4.1.2.5 Leucovorin (folinic acid) (FOL) (control vs drug vs drug+EGCG) 
Monotherapy with FOL at a dose of 112 ng/well induces an increase in cell viability compared 
to the control. Combination therapies of this drug with GTEE ([EGCG] = 0.5 and 5 μg/mL), MGTE 
([EGCG] = 0.5 and 5 μg/mL), GTE ([EGCG] = 0.5 and 5 μg/mL)  have also been tested. For the 
lowest EGCG concentrations cell viability was significantly increased compared to controls (similar 
to monotherapy), but for the highest EGCG concentrations there was a slight decrease in the 
number of living cells (Figure 36). The fact that there is an increase and not a reduction in cell 
viability compared with the control is linked to the fact that this drug is used in therapy to reduce 
the toxic effects of other chemotherapy drugs and to preserve healthy cells. 
 
Figure 36: Extremes and quartiles diagrams for MTT tests: controls, FOL, FOL + GTEE 0.5 and 5 μg/mL, 
FOL + MGTE 0.5 and 5 μg/mL, FOL + GTE 0.5 and 5 μg/mL. 
 
4.1.2.6 Oxaliplatin (OX) (control vs drug vs drug+EGCG) 
OX monotherapy at a dose of 23.8 ng/well reduced cell viability compared to control, however, 
not very marked. It became higher when the compound GTEE ([EGCG] = 0.5 and 5 μg/mL), MGTE 
([EGCG] = 0.5 and 5 μg/mL) or GTE ([EGCG] = 0.5 and 5 μg/mL)  were added to the drug. MGTE 
and GTE combination therapy ([EGCG] = 5 μg/mL and 0.5 μg/mL), respectively, have not been 
shown to significantly reduce cell viability if compared to the drug alone, whereas GTEE ([EGCG] = 
0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 μg/mL) and GTE ([EGCG] = 5 μg/mL) combination 
therapy produced a marked decay on cell viability when the same comparison were made (Figure 
37). 
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[A] [B] 
Figure 37: Extremes and quartiles diagrams for MTT tests: controls, OX, OX + GTEE 0.5 and 5 μg/mL, OX + 
MGTE 0.5 and 5 μg/mL, OX + GTE 0.5 and 5 μg/mL [A]; OX, OX + GTEE 0.5 and 5 μg/mL, OX + 
MGTE 0,5 μg/mL, OX + GTE 5 μg/mL [B]. 
 
4.1.2.7 Capecitabine + Oxaliplatin (CAPOX) combined regimen (control 
vs drug vs drug+EGCG) 
CAPOX therapy at the studied doses (CAP = 560 ng/well, OX = 36.4 ng/well) reduced cell 
viability if compared to the control; however, the decrease in cell viability was not very marked 
(Figure 38A). It became larger when GTEE ([EGCG] = 0.5 and 5 μg/mL) or MGTE ([EGC G] = 0.5 
μg/mL) were added to this combination of drugs (Figure 38B). On the other hand, GTE ([EGCG] = 
0.5 and 5 μg/mL) and MGTE ([EGC G] = 5 μg/mL) combination therapy had not been shown to 
reduce viability compared to the combined regimen.  
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[A] [B] 
Figure 38: Extremes and quartiles diagram for MTT tests: controls, CAPOX, CAPOX + GTEE 0.5 and 5 
μg/mL, CAPOX + MGTE 0.5 and 5 μg/mL, CAPOX + GTE 0.5 and 5 μg/mL [A]; CAPOX, CAPOX 
+ GTEE 0.5 and 5 μg/mL, CAPOX + MGTE 0.5 μg/mL [B]. 
 
4.1.2.8 Capecitabine + Irinotecan combined regime (CAPIRI) (control vs 
drug vs drug+EGCG) 
CAPIRI therapy at the studied dose (CAP = 560 ng/well, IRI = 70.0 ng/well) produced a 
decrease in cell viability comparable to the control. When GTEE ([EGCG] = 0.5 and 5 μg/mL), 
MGTE ([EGCG] = 0.5 and 5 μg/mL) or GTE ([EGCG] = 0.5 and 5 μg/mL) were added to the 
treatment, cell viability decreased more markedly than with the monotherapy (Figure 39A). In 
particular, the decrease in cell viability was greater with GTEE ([EGCG] = 0.5 and 5 μg/mL) or 
MGTE ([EGCG] = 0.5 μg/mL) combined with the chemotherapy drug. In fact, in these cases, the 
Kruskal-Wallis test showed a statistically significant difference in cell viability between control, 
therapy and combination therapy (Figure 39B). 
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[A] [B] 
Figure 39: Extremes and quartiles diagrams for MTT tests: controls, CAPIRI, CAPIRI + GTEE 0.5 and 5 
μg/mL, CAPIRI + MGTE 0.5 and 5 μg/mL, CAPIRI + GTE 0.5 and 5 μg/mL [A]; CAPIRI, CAPIRI + 
GTEE 0.5 and 5 μg/mL, CAPIRI + MGTE 0.5 μg/mL [B]. 
 
4.1.2.9 5-Fluorouracil + Leucovorin + Irinotecan combined regime 
(FOLFIRI) (control vs drug vs drug+EGCG) 
Treatment with FOLFIRI at the studied dose (5-FU = 0.1 ng/well, FOL = 5.6 ng/well, IRI = 50.4 
ng/well) induced a reduction in cell viability if compared with the control. When GTEE ([EGCG] = 
0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 μg/mL) or GTE ([EGCG] = 0.5 and 5 μg/mL) were 
added to the treatment, cell viability decreased approximately similarly in all cases, and more 
markedly than the therapy only (Figure 40A). In particular, GTEE ([EGCG] = 5 μg/ml) and MGTE 
([EGCG] = 0,5 μg/ml) were found to be the most effective in helping to reduce cell viability, as 
shown in Figure 40B, that highlights the percentages of cell viability compared to therapy alone, 
but anyhow, this greater reduction is not statistically significant. 
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 [A] [B] 
Figure 40: Extremes and quartiles diagrams for MTT tests: controls, FOLFIRI, FOLFIRI + GTEE 0.5 and 5 
μg/mL, FOLFIRI + MGTE 0.5 and 5 μg/mL, FOLFIRI + GTE 0.5 and 5 μg/mL [A]; and graph that 
highlights the percentage of cell viability of the drug-extract combination compared to the drug 
alone [B]. 
 
4.1.2.10 5-Fluorouracil + Leucovorin + Oxaliplatin combined regime 
(FOLFOX) (control vs drug vs drug+EGCG) 
Therapy performed with FOLFOX at the studied doses (FOL = 112 ng/well, 5-FU = 112 ng/well and 
OX = 23.8 ng/well) moderately reduced cell viability if compared with control. The addition of GTEE 
([EGCG] = 0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 μg/mL) or GTE ([EGCG] = 0.5 and 
5 μg/mL) to the therapy produced a decrease in cell viability approximately identical to the 
decrease produced by the drug alone. There were no statistically significant reductions in cell 
viability (Figure 41). GTEE ([EGCG] = 0.5 μg/mL) combination therapy reduced cell viability more 
than any other extract brands and concentrations, although this decrease was not statistically 
significant if compared to the decrease produced by the drug or by the drug combined with the 
other extracts. 
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Figure 41: Extremes and quartiles diagrams for MTT tests: controls, FOLFOX, FOLFOX + GTEE 0.5 and 5      
μg/mL, FOLFOX + MGTE 0.5 and 5 μg/mL, FOLFOX + GTE 0.5 and 5 μg/mL. 
 
4.1.3 MCF-7 cell line 
Due to the lack of new chemotherapy drugs for breast cancer to test, similar in vitro studies 
(done for WiDr) could not be performed for the MCF-7 cell line. The presented data, which were 
the basis for MCF-7 in vivo studies, have been coupled to the ones obtained in previous works. 
Considering previous studies, for the MCF-7 cell line the number of applications giving 
statistically significant results was 6 applications (7 days). 
 
4.1.3.1 Tea extract 
The EGCG enriched green tea extract used in the following in vitro experiments was the 
Green Tea Extract (GTE) powder. The extract concentrations used were 0.5 µg/mL and 5 µg/mL. 
The first tests were carried out with this tea extract. The graph below shows the comparison 
between the MTT values of the extract and the control. Considering the results provided by the 
Kruskal-Wallis statistical test, the GTE extract for a 5 µg/mL concentration showed statistical 
significance regarding the control (p ≤ 0.001). For GTE extract with a 0.5  µg/mL concentration a 
p ≤ 0.01 was determined. Cell viability with GTE 5 µg/mL is significantly lower than the control and 
than GTE 0.5 µg/mL (Figure 42).  
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Figure 42: Extremes and quartiles diagram for MTT tests: controls, GTE 0.5 and 5 μg/mL. 
 
4.1.3.1 Capecitabine (CAP) (control vs drug vs drug+EGCG) 
Using monotherapy with this antimetabolite drug in a single application (1000 mg/m2) for the 7-
day incubation period, alone and in association with the GTE extract at different EGCG 
concentrations (0.5 and 5 µg/mL) were analyzed, for a total of 6 applications (7 days). Therefore, 
using the Kruskal-Wallis test, the control was compared with CAP and with CAP in association with 
the extract and then the drug in monotherapy was compared with the drug associated with the 
extract. 
Statistical analysis showed a decrease in cell viability considering each substance compared 
to the control (p ≤ 0.001) (Figure 43A). Furthermore, the association of CAP to GTE at both 
concentrations were more cytotoxic than CAP alone (p ≤ 0.01), although the two associations 
showed no significant differences between them, thus having a similar effect (p > 0.05) (Figure 
43B). 
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[A] [B] 
Figure 43: Extremes and quartiles diagrams for MTT tests: controls, CAP, CAP + GTE 0.5 and 5 μg/mL [A];   
CAP, CAP + GTE 0.5 and 5 μg/mL [B]. 
 
4.1.3.2 Docetaxel (DOT) (control vs drug vs drug+EGCG) 
Applying monotherapy with this taxane type of drug, performing a single application (60 
mg/m2) for the 7-day incubation period, its isolated action and its action in association with GTE 
extract at different EGCG concentrations (0.5 and 5 µg/mL) were analyzed. Therefore, using the 
Kruskal-Wallis test, comparison between groups was performed: the control was compared with 
the drug and with the combined therapy (DOT + extract) and then the drug in monotherapy was 
compared with the combined therapy. 
The decrease in cell viability is statistically significant for all substances if compared with 
control (p≤ 0.01) (Figure 44A). 
The associations DOT+GTE showed no significant differences from DOT alone (p > 0.05), 
although they appear to be more statistically effective. It will be necessary to increase the number 
of samples to see if differences arise. 
Comparing the two associations DOT+GTE, a statistically significant difference was found 
(p < 0.05), being DOT+GTE 0.5 combination more cytotoxic than the one with the highest EGCG 
concentration, visually it also looks more cytotoxic than the others compared substances (Figure 
44B). 
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[A] [B] 
Figure 44: Extremes and quartiles diagram for MTT tests: controls, DOT, DOT+ GTE 0.5 and 5 μg/mL [A];      
DOT, DOT + GTE 0.5 and 5 μg/mL [B]. 
 
4.1.3.3 Doxorrubicin (DOX) (control vs drug vs drug+EGCG) 
Applying monotherapy with this anthracycline type of drug, for a single application (60 mg/m2) 
for the 7-day incubation period, its isolated action and its action in association with GTE extract at 
different EGCG concentrations (0.5 and 5 µg/mL) were analyzed. Therefore, using the 
Kruskal-Wallis test, comparison groups were performed: the control was compared with the drug 
and with the combined therapy (DOX + extract) and then the drug in monotherapy was compared 
with the combined therapy. 
The decrease in cell viability is statistically significant only for the comparison of substances 
with the control (p ≤ 0.01) (Figure 45A). 
For Doxorubicin, through statistical analysis, it was found there was no statistically significant 
difference between DOX and DOX associated with GTE (p = 1.000) as well as between 
DOX + GTE 0.5 and DOX + GTE 5 (p = 0.273) (Figure 45B). From the graph of the Figure 45B we 
can observe the combined therapy has increased the cytotoxicity only slightly compared to the 
DOX alone. 
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[A] [B] 
Figure 45: Extremes and quartiles diagram for MTT tests: controls, DOX, DOX + GTE 0.5 and 5 μg/mL [A];      
DOX, DOX + GTE 0.5 and 5 μg/mL [B]. 
 
4.1.3.4 5-Fluoracil (5-FU) (control vs drug vs drug+EGCG) 
Applying monotherapy with this anti-metabolite type of drug, performing a single application 
(500 mg/m2) for the 7-day incubation period, its isolated action and its action in association with 
GTE extract at different EGCG concentrations (0.5 and 5 µg/mL) were analyzed. Therefore, using 
the Kruskal-Wallis test, comparison groups were performed: the control was compared with the 
drug and with the combined therapy (5-FU + extract) and then the drug in monotherapy was 
compared with the combined therapy. 
The decrease in cell viability is statistically significant only when comparing substances with 
control (p ≤ 0.05) (Figure 46A). 
The association of 5-FU with GTE at different concentrations appear to be visually more 
effective than 5-FU alone, but the difference was not significant (p > 0.5) (Figure 46B). Maybe, a 
more significant response could be reached increasing the number of samples. 
Comparing the two combinations, 5-FU + GTE 0.5 µg/mL and 5-FU + GTE 5 µg/mL, no 
significant differences were found (p = 0.817), being equally cytotoxic for the cell line. 
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[A] [B] 
Figure 46: Extremes and quartiles diagram for MTT tests: controls, 5FU, 5FU + GTE 0.5 and 5 μg/mL [A];      
5FU, 5FU + GTE 0.5 and 5 μg/mL [B]. 
 
4.1.3.5 Paclitaxel (PAX) (control vs drug vs drug+EGCG) 
Applying monotherapy with this taxane type of drug, performing a single application (175 
mg/m2) for the 7-day incubation period, its isolated action and its action in association with GTE 
extract at different EGCG concentrations (0.5 and 5 µg/mL) were studied. Therefore, using the 
Kruskal-Wallis test, comparison between groups was performed: the control was compared with 
the drug and with the combined therapy (PAX + extract) and the drug in monotherapy with the 
combined therapy. 
The decrease in cell viability is statistically significant when comparing substances with the 
control (p ≤ 0.001) (Figure 47A). 
Paclitaxel assays showed that the PAX + GTE combination with EGCG, in both 
concentrations, showed higher cytotoxicity than PAX alone (p ≤ 0.01), demonstrating that the 
combined therapy potentiated the cytotoxic effect of Paclitaxel, which in itself already had high 
cytotoxicity. Visually PAX + GTE 0.5 µg/mL combination and PAX + GTE 5 µg/mL combination 
showed the same cytotoxicity, in fact, no statistically significant differences were highlighted (p > 
0.05) (Figure 47B). More tests will be needed to consolidate the results. 
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[A] [B] 
Figure 47: Extremes and quartiles diagram for MTT tests: controls, PAX, PAX + GTE 0.5 and 5 μg/mL [A];      
PAX, PAX + GTE 0.5 and 5 μg/mL [B]. 
 
 
4.2 in vivo studies 
4.2.1 Weight and tumor area monitoring of the animals in the 
study 
As previously noted in Chapter 3, a colon cancer and a breast cancer cell line were injected 
into a non-orthotopic model: Balb/C nude mice (males for colon cancer and females for breast 
cancer). When the tumor developed and reached about 1 mm2 size, the animals started the 
therapy with green tea extract. Animal weight and tumor size were monitored weekly. Two groups 
of animals were tested for both cell lines: an injected group drinking only water and an injected 
group drinking the tea extract. The animals weight control essentially helped to understand if the 
treatment was very intense, in fact in the literature it is described that the consumption of green tea 
could cause weight loss. 
The graphs in Figure 48 and 49 illustrate the variation concerning the tumor area.  
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Figure 48: Trend of tumor size in animals injected  Figure 49: Trend of tumor size in animals injected  
     with the WiDr cell line (groups 1-2).         With the MCF-7 cell line (groups 3-4). 
 
Looking at these figures, it turns out that the tea extract therapy was effective and the tumor 
size was reduced if compared to the control (red lines). The tumor did not disappear, but its 
development slowed down. 
The graphs in Figure 50 and 51 illustrate the variation in animal weight.  
 
Figure 50: Trend of animal weight in animal injected  Figure 51: Tend of animal weight in animals injected  
     with the WiDr cell line (groups 1-2).         with the MCF-7 cell line (groups 3-4). 
 
Considering the controls, the animals weight remained approximately constant for both cell 
lines. In treated mice, as shown in the literature, a reduction in weight was seen but this reduction 
was followed by a new increase in weight. In conclusion, there were no significant changes in 
animal weight from the start of treatment to necropsy. 
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4.2.3 Positron emission tomography (easyPET) 
After the induction process of colon and breast cancer in the animal model (Balb/c nude mice), 
the tumors evolution was examined with the help of the easyPET-3D system, through the detection 
of 18F-FDG radiopharmaceutical activity.  
The aim was to perform PET acquisitions along the time of the experiment. Images of control 
animals have been performed applying a previously optimized protocol. Then each animal has 
been evaluated by imaging according to the data collected during the visual weekly observation. 
Another image has been acquired at key points of the animal model experiment: 1) before the 
tumor could be perceived externally perceiving, 2) during green tea “therapy”, and 3) post-
“therapy”. This equipment was developed and tested by a team in collaboration with the University 
of Aveiro. The team has two funded projects: CENTRO-01-0247-FEDER-017823, SII and DT 
17823; PTDC/bbb-img/4909/2014. The software is still being developed and optimized, but image 
acquisition, reconstruction and processing is already possible. 
Animals have been studied using this micro PET system prototype but, as already mentioned, 
these animals (nude mice) are very sensitive and could easily undergo complications due to 
anesthesia, glucose reduction, lowering of body temperature, etc, hence every manipulation was 
performed with great care and attention. The image acquisition of this equipment (built with the 
technology designed by the team) has been very successful as it has allowed to detect the 
existence of very small tumors. Furthermore, it was also proven that tumors could be detected 
even when they were not yet visible externally. This means that it plays a very important role in the 
diagnosis and monitoring of tumor volume during therapy, in order to be able to evaluate its effects 
in vivo. The coupled software allowed to reconstruct and process the acquired images that can be 
shown in 3 planes: transverse, coronal and sagittal, as illustrated in the following Figure 52. 
[A] [B] [C] 
Figure 52: Example of easyPET-3D acquisition: transverse [A], coronal [B] and sagittal [C] plane. 
This equipment was able to identify where the radionuclide was accumulated within the animal 
body and, in particular, which sites had the highest consumption of glucose. In the studied cases, 
the accumulation was highlighted over the dorsal area (as this is the point where the tumor was 
injected and developed), over the bladder (since 18F-FDG has mainly by renal excretion), and 
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sometimes over the joints, if an inflammation (even though small) were present, showing an 
increase in glucose consumption similar to the other mentioned sites. 
The presented images have been extrapolated using the Amide, which allows viewing the 
processed files. To highlight the tumor, the bladder area was obscured, when it was present in the 
image. The tumor images obtained were analyzed as follows: the region of interest containing the 
tumor was selected and the SUV was calculated. The results were then compared to evaluate the 
tumor progression. 
The SUV (“standardized uptake value”) is a dimensionless ratio used by nuclear medicine 
professionals to distinguish between “normal” and “abnormal” levels of uptake. Its largest use is in 
current clinical practice, being a relative measure of FDG uptake. The basic expression for SUV is  
    
 
  
 
 
where r is the radioactivity concentration measured by the PET scanner within a region of interest 
(ROI) previously identified,    is the decay-corrected amount of injected FDG [µCi], and w is the 
weight of the patient [g], which is used for a distribution volume of tracer.  
Hence, SUVs reflect the relative adsorption of FDG and higher SUVs are associated to greater 
regional metabolic activity. It may be useful as a measure to follow the metabolic activity of a tumor 
over time within the same patient and to compare different subjects within a research study under 
defined conditions. 
For the following analysis, the SUV_Mean was considered. This value corresponds to the 
average value of all pixels inside the ROI, being an approximation of what would be the expected 
SUV in the tumor. SUVs > 1 are considered high values, corresponding to an abnormal glucose 
metabolism.  
The following Figure (Figure 53) shows SUV means inside the ROIs enclosing the tumor. In 
this case, the acquisitions were performed when the tumors were not visible from the outside. 
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Figure 53: Extreme and quartile diagrams showing SUV mean values for MCF-7 and WiDr 
cell lines. In these mice tumor was not visible externally. 
The results of Figure 53 showed that the easyPET-3D system was able to detect the abnormal 
metabolism of tumor cells before the tumor mass was visible externally, by naked eye. This result 
is important because it shows the potential of this research tool. In fact, by identifying the tumor as 
soon as it develops (before causing visible anatomical changes), treatment can be started when 
the tumor is still in an early stage, contributing to a better success of the experiments. Furthermore, 
comparing the two tumor cell lines it is showed that MCF-7 takes longer to develop (lower SUVs in 
the same time interval), while the WiDr cell line is able to reach high SUVs (ex. SUV = 4) in shorter 
time (less than a month), proving that colon cancer is more aggressive than breast cancer in this 
animal species (Balb/c nude mice). 
 
Figures 54,55 show the mean SUVs over time, extrapolated from Amide, for control animals 
(injected with cancer cells, not receiving the treatment) and treated animals, for both cancer cell 
lines. 
 
Figure 54: Graph showing the trend of SUVs in treated and untreated animals, for breast cancer cell line. 
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Figure 55: Graph showing the SUVs trend in treated and untreated animals, for colon cancer cell line. 
 
Considering the above results, it was concluded that control animals showed an increasing 
SUVs trend over time, reflecting a constant growth of the tumor. On the other hand, the animals 
that received the EGCG compound showed a decreasing in SUVs trend, indicating a slowdown in 
tumor growth and the effectiveness of the treatment. 
What matters most in this analysis is not the final value of the SUV means (since it could 
depend on the number of cells initially inoculated in the animal, on its age or on its metabolic 
characteristics), but the SUV means trend over time: its decrease, in fact, means a reduction in 
tumor activity over time, suggesting benefits of treatment. 
These graphs also reinforce the idea that WiDr cells grow faster than MCF-7, being able to 
lead to a more dangerous oncological disease (higher SUVs in a shorter period of time). As for the 
MCF-7, it is easier to treat the tumor from an early stage because its development is slower, 
allowing an early detection. 
To confirm the excellent performance of the easyPET-3D system in identifying even small 
activity accumulations, the acquisition of a tested animal is showed. In this case-study, in addition 
to the activity accumulation caused by the presence of the inoculated tumor, another site of high 
activity was detected, corresponding to the left knee joint (Figure 56). 
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[A] [B] [C]  
Figure 56: Positron emission tomography image obtained using the easyPET-3D system, observing the 
activity of 
18
F-FDG radiopharmaceutical on 3 different planes: transverse [A]; coronal [B]; 
sagittal [C]. The bladder was darkened to highlight the tumor and the inflammation site. 
Since glucose is present in larger amounts in tumor areas or in those with more intense 
muscle activity, the team tried to identify the cause of this abnormal activity. It has been noted that 
the mouse had knee edema. The fluid was removed from the knee and it was found to be 
inflammatory cells. After performing a rudimentary necropsy, it was observed that the mouse was 
born with a malformation of the right leg, having no fibula. The absence of this bone caused the 
mouse to make more strain on the opposite leg, causing inflammation and therefore accumulation 
of fluid in the left knee. 
 
Figure 57: Illustrative image of the inflamed knee area [A]; representative figure of the puncture for 
accumulated liquid collection [B]; rudimentary necropsy identifying the malformation of mouse 
right leg. 
Based on these results, it is noted that easyPET can capture gamma rays, producing sensitive 
and specific images to detect metabolic changes, allowing the diagnosis of a tumor mass even 
before it is visible externally. Moreover, thanks to the SUV calculation, the system allows to 
evaluate the progression/regression of the tumor even in a quantitative way. 
This example confirms the excellent potential of this imaging research system. 
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4.2.3 Histological studies 
At the end of the in vivo studies, animals were observed and tumors were collected for routine 
histological processing and observation under the optical microscope. The histological study was 
performed at the Experimental Pathology laboratory of the FMUC Department of Dentistry. 
In all animals, macroscopic observation indicated that the main organs (stomach, intestine, 
lung, liver and kidney) were normal and no metastases developed. When analyzing the histological 
images, no differences were shown in areas surrounding the tumor, when compared with healthy 
animal tissues. This means neither tumor cell injection nor GTE green tea extract solution 
treatment altered architecture and physiology of tissues and organs. 
Below are some routine optical microscopy images obtained from the samples of tumor 
(Figure 58-60). 
 
Figure 58: histological section of a WiDr tumor collected on 8 May 2019 (magnification of 200x). A 
glandular [1] and fibrous [2] tumor area and an inflammatory infiltrate [3] are identified. The 
dark blue spotted shaped are PMN (polymorphonuclear neutrophils). 
 
Figure 59: histological section of a MCF-7 tumor collected on 1st July 2019 (magnification of 200x). 
Muscular fibers longitudinally sectioned [1], muscular fiber circulary sectioned [2], tumor 
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remaining glandular area [3], thin skin layer [4], and fibrosis + fat cells (corresponding to the 
remaining tumor structures) [5] are identified. 
 
 
Figure 60: histological section of a WiDr tumor collected on 1
st
 July 2019 (magnification of 200x). Dermis [1], 
blood vessels [2], muscular mucosa [3], subcutaneous areolar tissue [4] and tumor [5] are 
identified.   
Tissues and structures in the area surrounding the tumor did not show alterations with respect 
to the tissues and structures of healthy animals, suggesting the non-aggressiveness of the 
treatment with tea extract. 
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Chapter 5 
5. Conclusion 
In this chapter the results presented in the previous sections are discussed and conclusions 
are drawn. The limits observed during this study are highlighted and future prospects for further 
research are indicated.  
In in vitro studies, more specifically for the performed MTT tests, the cytotoxic potential of 
several monotherapy drugs and their combinations was studied, as well as their combination with 
GTEE ([EGCG] = 0.5 and 5 μg/mL), MGTE ([EGCG] = 0.5 and 5 μg/mL) and GTE ([EGCG] = 0.5 
and 5 μg/mL). This extract, for each brand, has been shown to have a positive effect on cancer 
cells, decreasing their vitality. Furthermore, this extract has been shown to have a good synergy 
with most of the drugs tested: CAP, 5-FU, IRI, OX, PAX, CAPOX, CAPIRI and FOLFIRI. In these 
cases, when the extracts were added to the treatment, there was a significant reduction in 
biologically cell viability in at least one of the concentrations and in at least one of the brands. For 
FOLFOX there was a reduction of cell viability compared to the control when the drug was used on 
its own, however when the extracts were added to the treatment no more changes in vitality 
occurred. Compared to this drug, the extract seems to have no particular effects. In the case of 
FOL there was an increase in cell viability in monotherapy and in combination with all the extracts, 
with a small reduction in viability only with GTEE (EGCG] = 0.5 and 5 μg/mL) and MGTE ([EGCG] 
= 5 μg/mL). These results were expected since FOL is a drug used in combination with other 
chemotherapeutic drugs, not in monotherapy, to preserve healthy cells and to reduce the toxic 
effects of folic acid antagonist drugs, thus having a defense function and cell blood protection. 
The problems that can occur for these types of studies may be due to the phase of the cell 
cycle in which the cells are found when therapy starts. In fact, since the cells used in these studies 
were collected from different culture flasks, the relationships between cells in the same cell division 
stage should be different, so the cytotoxic potential of drugs and combinations is different. 
In the future, cytometric studies with apoptose/necrosis markers should be performed to 
identify the phase of the cell cycle, thus enabling to understand these differences, since the drugs 
act at different stages of cell development.  
As for the in vivo tests, this type of tumor has been successfully inoculated in the lineage of 
Balb/c nude mice and green tea therapy has worked: a slowdown in tumor growth was initially 
verified and subsequently an effective reduction, although not very large, compared to the control 
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(drinking only water), in which the tumor grew faster and was never reduced. These animals were 
sacrified when the tumor reached the maximum allowed size and, through necropsy, it was verified 
that there were no metastases in other organs, nor other alterations suggesting that the therapy 
was harmful to the animal. 
The results are promising and significant at biological level, being necessary to increase the 
number of tested animals in order to reinforce the statistics. 
In these types of experiments, however, there are always so many variables that can lead to 
different and bad results: tumors can develop more or less depending on the age of the animal and 
the immunity of individuals acquired over time, over the generations, due to breading crossings 
with family. Along the generations, in fact, immune-compromised animals start to acquire some 
immunity and, thus starting to show some fur. In fact, some of the injected animals had some fur 
on their heads or around their eyes. This is probably why animals have different "response times". 
Another factor that can lead to different results and developing speeds is the number of 
injected cells: the amount of cells will never be exactly the same from one animal to another. 
Unlike previous studies, in this case the treatment with EGCG did not lead to an excessive 
decrease of the animal weight, allowing to continue the study, avoiding the interruption of the 
experiment for ethical and legal reasons. In fact, this animal species is very fragile and small 
(about 20 g), therefore even low weight losses could be significant. For this type of study, in order 
to proceed in the best way, it is mandatory that animal is as "strong" as possible to withstand the 
treatment. It would also be positive to increase the number of animals tested in vivo, trying to 
choose animals the most similar as possible. 
With easy PET-3D equipment, it was possible to observe the tumor in mice before it was 
visible externally. In another parallel project it was also possible to observe distinct areas of the 
mice brain, revealing that the equipment is reliable, has good resolution and sensitivity. However, 
there are some limitations that the research group would like to improve. The acquisition tube only 
allows small animals to be studied (adult RNU rats are too large); the bed where mice are placed 
should be heated directly, taking into account the innate fragility of the species and the fragility 
acquired after anesthesia. This has been achieved heating the animal with a coupled external 
system. Furthermore, a CT or a MRI system should be combined with PET equipment in order to 
acquire morphological information for posterior images fusion, thus improving observation of the 
contours of the animal. This feature will allow to identify other morpho-anatomical structures, 
making the visualization of the tumor, inflammations or other organs more intuitive (the images 
acquired by this equipment need a trained observer). In any case, easyPET-3D has fulfilled all the 
previewed requirements. 
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At the end of the in vivo studies, or when animals had to be occized, major organs and tissues 
excised from the tumor injection area were collected to verify that there were no metastases. There 
were no anatomical differences between animals injected with cancer cells drinking only water and 
animals having continuous oral administration of green tea. Since no organ had abnormal 
differences nor alterations, it could be concluded that the treatment did not affect their morphology 
or functional. Observing the tumor masses of the treated animals and those drinking only water, it 
was possible to deduce that in the treated animals the tumor had reduced dimensions and less 
glandular areas (being replaced by fat and collagen fibers), revealing treatment effectiveness. 
In the future, the number of replicates for in vitro studies should be increased in order to 
enhance statistical significance. Other drug dosages should be tested in cases where it was not 
possible to detect the existence of synergies between the EGCG extract and the drug; where the 
EGCG effect was really positive, future works should try to reduce the therapy drug dosage, as the 
drug has many side effects; new drugs should be tested; the phase of the cell cycle at the time of 
death should be identified to better understand the mechanisms of action of EGCG and the 
signaling chains in which it can act; immunohistochemical tests (the WiDr cell line produces a CEA 
antigen) should be performed to detect the expression of characteristic proteins using the 
antigen/antibody principle to easily identify cancer cells. Other antigens and markers of interest 
that can be used in sequence are: CD44, involved in cell proliferation and migration; Ki67, cell 
proliferation marker; suppressor genes (p53 and p21) and VEGF angiogenesis markers.  
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Annexe II - DGAV statement 
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Annexe III 
 
[A] Trypan blue 
The procedure consists of preparing 4 g trypan blue in 100 mL distilled water. 
 
[B] PBS 
The procedure consists of adding to a sterile 500 mL Schott bottle (Duran, 00361668, Germany) 
7.4 g of NaH2PO4, 3.6 g of NaCl, 0.215 g of KH2PO4 and 500 mL of ultrapure water. At the end, the 
pH is adjusted to 7.4 and the vial is closed and labeled. 
 
[C] Acid isopropanol 
The procedure consists of adding to a sterile 500 mL Schott bottle (Duran, 00361668, Germany) 
1.75 mL of fuming hydrochloric acid at 37% and 498.25 mL of 2-propanol at 99,5%. 
